¡¶ÂýÐÔÒÒÐ͸ÎÑ×·ÀÖÎÖ¸ÄÏ¡·2010°æ½ñÈÕÔÚ¾©·¢²¼ ¡¡¡¡ ÖлªÒ½Ñ§»á¸ÐȾ²¡Ñ§»á·Ö»á
¡¡¡¡2010Äê12ÔÂ10ÈÕÐÇÆÚÎåÉÏÎ磬ÔÚ±±¾©Ê×¶¼ÈËÃñ´ó»áÌÃÖØÇìÌü£¬ÓÉÖлªÒ½Ñ§»á¸Î²¡Ñ§·Ö»á¡¢ÖлªÒ½Ñ§»á¸ÐȾ²¡Ñ§·Ö»á£¬×éÖ¯ÕÙ¿ªÁË¡¶ÂýÐÔÒÒÐ͸ÎÑ×·ÀÖÎÖ¸ÄÏ¡·2010°æÐÂÎÅ·¢²¼»á¡£²Î»áÓÐÀ´×ÔÁ½¸öѧ»áÃûÓþÖ÷ÈÎίԱׯ»ÔԺʿºÍÎÌÐÄ»ª½ÌÊÚ¡¢Á½¸öѧ»áµÄÖ÷ÈÎίԱ¡¢ºòÈÎÖ÷ÈÎίԱ¡¢¸±Ö÷ÈÎίԱ¡¢²¿·Ö³£Î¯ºÍ²ÎÓëÐÞ¶©Ö¸ÄϵÄר¼Ò¡£²¿·Ö±¨Ö½ºÍÔÓÖ¾µÄ¼ÇÕßÓ¦Ñû²Î»á¡£ÖлªÒ½Ñ§»á¡¢Öйú¼²²¡¿ØÖÆÖÐÐĺ͹ú¼ÒÎÀÉú²¿ÓйØÁìµ¼³öϯ·¢²¼»á²¢½²»°¡£ÖлªÒ½Ñ§»á¸ÐȾ²¡Ñ§·Ö»áÖ÷ÈÎίԱ¡¢ÖлªÒ½Ñ§»á¸Î²¡Ñ§·Ö»áÖ÷Èμ̶ּ«½ÌÊÚµÈÖ÷³Ö»áÒé¡£
¡¡¡¡»áÉÏ£¬×¯»ÔԺʿ¶Ô2005°æ¡¶ÂýÐÔÒÒÐ͸ÎÑ×·ÀÖÎÖ¸ÄÏ¡·×÷Á˾«²Ê»Ø¹Ë£¬ÎÌÐÄ»ª½ÌÊÚÈÈÇéÑóÒçµØ½²ÊöÁËÖ¸ÄϵÄÒâÒåºÍÖÆ¶¨Ö¸ÄÏÒÔÀ´È¡µÃµÄ³É¾Í¡£Ëæºó£¬¼Ö¼Ì¶«½ÌÊÚ¼òÃ÷¶óÒªµØ½éÉÜÁË2010°æÖ¸ÄϵÄÐÞ¶©¹ý³Ì£¬²¢Óë2005°æÖ¸ÄÏ×÷ÁËÌá¸ÙÐԵıȽϡ£×îºó£¬ºî½ðÁÖ½ÌÊÚ½éÉÜÁËаæÖ¸ÄÏÍÆ¹ã¼Æ»®¡£ ¡¡¡¡
ÖйúÂýÐÔÒҸλ¼ÕßÔ¼2000ÍòÀý аæ·ÀÖÎÖ¸ÄÏ·¢²¼ ¡¡¡¡ À´Ô´£ºÖйúÐÂÎÅÍø
¡¡¡¡ÖÐÐÂÉç±±¾©12ÔÂ10ÈÕµç (¼ÇÕß ÔøÀûÃ÷)ÖйúÄÚµØÏÖÓÐÂýÐÔÒÒÐ͸ÎÑײ¡¶¾¸ÐȾÕßÔ¼9300ÍòÈË£¬ÆäÖÐÏÖÖ¢»¼Õß2000ÍòÀý¡£ÕâÊÇÖлªÒ½Ñ§»á¸Î²¡Ñ§·Ö»á½ñÌ칫²¼µÄ×îÐÂÊý¾Ý¡£
¡¡¡¡ÓÉÖйú×ÔÖ÷¿ªÕ¹µÄÈ«¹úÒÒ¸ÎÁ÷Ðв¡Ñ§µ÷²é±íÃ÷£¬È«¹ú1ÖÁ59ËêÈËȺÒҸαíÃæ¿¹ÔЯ´øÂÊЯ´øÂÊΪ7.18%£¬±È1992Äê9.75%µÄϽµ26.36%£¬ÇÒÄêÁäԽС£¬Ï½µ·ù¶ÈÔ½´ó£»³ÇÊС¢Å©´åÈËȺ²îÒì²»ÏÔÖø£¬Î÷²¿µØÇø¸ßÓÚ¶«²¿µØÇø¡£ÆäÖÐ5ÖÁ14ËêÈËȺΪ2.42%¡£15ÖÁ59ËêÈËȺÒҸαíÃæ¿¹ÔЯ´øÂÊ×î¸ß£¬´ï8.57%¡£
¡¡¡¡Îª¹æ·¶ÂýÐÔÒҸεÄÔ¤·À¡¢Õï¶ÏºÍÖÎÁÆ£¬ÖлªÒ½Ñ§»á¸Î²¡Ñ§·Ö»áºÍÖлªÒ½Ñ§»á¸ÐȾ²¡Ñ§·Ö»áµÈ½ñÌìÕýÊ½ÍÆ³ö2010Äê°æ¡¶ÖйúÂýÐÔÒÒÐ͸ÎÑ×·ÀÖÎÖ¸ÄÏ¡·¡£
¡¡¡¡Öйú¹¤³ÌԺԺʿׯ»Ô½ÌÊÚÖ¸³ö£¬Ð°æÖ¸ÄÏÊ×´ÎÄÉÈëÓÅ»¯ÖÎÁƲßÂÔ£¬Õâ¶ÔÌá¸ß²¡È˵ÄÒÀ´ÓÐÔ¡¢Ô¤·ÀÄÍÒ©¡¢Ëõ¶ÌÁƳ̡¢Ìá¸ßÁÆÐ§ºÍ½µµÍÒ½ÁÆ·ÑÓü«ÎªÖØÒª¡£
¡¡¡¡ËûÌṩµÄµ÷²éÊý¾ÝÏÔʾ£ºÖйú80%ÒҸλ¼ÕßÔÂÊÕÈëµÍÓÚ3000ÔªÈËÃñ±Ò£¬×Ô·Ñ»¼ÕßÕ¼µ½54%£¬²»ÄܳÐÊÜÿÔ¹ýǧµÄÖÎÁÆ·ÑÓã¬Óнü°Ë³ÉµÄ»¼Õß²»Äܼá³Ö´óÓÚÁ½ÄêµÄ¿¹²¡¶¾ÖÎÁÆ£¬ÔÒòÓ뻼Õß¾¼Ã¸ºµ£ÖØÃÜÇÐÏà¹Ø¡£ ¶øÓÅ»¯ÖÎÁÆ´ÓÁÆÐ§¡¢°²È«ÐԺͷÑÓÃÈý·½Ã棬Õë¶Ô²»Í¬ÈËȺָ¶¨ÊʺϵÄÖÎÁÆÔÔò£¬¿É±£Ö¤»¼Õß³¤ÆÚ½øÐп¹²¡¶¾ÖÎÁÆ¡£
¡¡¡¡¹ú¼ÒÎÀÉú²¿¡¢ÖлªÒ½Ñ§»á¡¢Öйú¸ÎÑ×·ÀÖλù½ð»á¡¢Öйú¼²²¡Ô¤·À¿ØÖÆÖÐÐĵĸºÔðÈËÒÔ¼°Öйú¸Î²¡ºÍ¸ÐȾ²¡ÁìÓòµÄר¼Ò100ÓàÈ˳öϯÁËаæÖ¸ÄÏ·¢²¼»á¡£
È«ÎÄÏÂÔØ£º
http://www.hbver.com/Soft/ygfz1/201012/50.html
¸½£ºÂýÐÔÒÒÐ͸ÎÑ×·ÀÖÎÖ¸ÄÏ2010Äê¸üа棨´ý¶¨¸å£©£¨È«ÎÄ£©
ÂýÐÔÒÒÐ͸ÎÑ×·ÀÖÎÖ¸ÄÏ2010Äê¸üа棨´ý¶¨¸å£© ¡¡¡¡ÖлªÒ½Ñ§»á¸Î²¡Ñ§·Ö»á ¡¡¡¡ÖлªÒ½Ñ§»á¸ÐȾ²¡·Ö»á
¡¡¡¡2010Äê12ÔÂ10ÈÕ
¡¡¡¡Îª¹æ·¶ÂýÐÔÒÒÐ͸ÎÑ×µÄÔ¤·À¡¢Õï¶ÏºÍÖÎÁÆ£¬ÖлªÒ½Ñ§»á¸Î²¡Ñ§·Ö»áºÍ¸ÐȾ²¡Ñ§·Ö»áÓÚ2005Äê×éÖ¯¹úÄÚÓйØ×¨¼ÒÖÆ¶©ÁË¡¶ÂýÐÔÒÒÐ͸ÎÑ×·ÀÖÎÖ¸ÄÏ¡·[1]¡£ ½ü5ÄêÀ´£¬¹úÄÚÍâÓйØÂýÐÔÒÒÐ͸ÎÑ׵Ļù´¡ºÍÁÙ´²Ñо¿È¡µÃºÜ´ó½øÕ¹£¬Îª´ËÎÒÃǶԱ¾Ö¸ÄϽøÐиüС£ ¡¡¡¡±¾Ö¸ÄÏÖ¼ÔÚ°ïÖúÒ½ÉúÔÚÂýÐÔÒÒÐ͸ÎÑ×ÕïÁƺÍÔ¤·À¹¤×÷ÖÐ×ö³öºÏÀí¾ö²ß£¬µ«²»ÊÇÇ¿ÖÆÐÔ±ê×¼£¬Ò²²»¿ÉÄܰüÀ¨»ò½â¾öÂýÐÔÒÒÐ͸ÎÑ×ÕïÖÎÖеÄËùÓÐÎÊÌâ¡£Òò´Ë£¬ÁÙ´²Ò½ÉúÔÚÃæ¶Ôijһ»¼Õßʱ£¬Ó¦ÔÚ³ä·ÖÁ˽âÓйر¾²¡µÄ×î¼ÑÁÙ´²Ö¤¾Ý¡¢ÈÏÕæ¿¼ÂÇ»¼Õß¾ßÌ岡Çé¼°ÆäÒâÔ¸µÄ»ù´¡ÉÏ£¬¸ù¾Ý×Ô¼ºµÄרҵ֪ʶ¡¢ÁÙ´²¾ÑéºÍ¿ÉÀûÓõÄÒ½ÁÆ×ÊÔ´£¬Öƶ©È«ÃæºÏÀíµÄÕïÁÆ·½°¸¡£ÎÒÃǽ«¸ù¾Ý¹úÄÚÍâµÄÓйؽøÕ¹Çé¿ö£¬¼ÌÐø¶Ô±¾Ö¸ÄϽøÐв»¶Ï¸üкÍÍêÉÆ¡£ ¡¡¡¡Ò»¡¢²¡Ôѧ ¡¡¡¡ÒÒÐ͸ÎÑײ¡¶¾ (HBV) ÊôÊȸÎDNA²¡¶¾¿Æ (hepadnaviridae)£¬»ùÒò×鳤Լ3.2kb£¬Îª²¿·ÖË«Á´»·×´DNA¡£ HBVµÄµÖ¿¹Á¦½ÏÇ¿£¬µ«65¡æ10 h¡¢Öó·Ð10 min»ò¸ßѹÕôÆø¾ù¿ÉÃð»îHBV¡£»·ÑõÒÒÍé¡¢Îì¶þÈ©¡¢¹ýÑõÒÒËáºÍµâ·ü¶ÔHBVÒ²ÓнϺõÄÃð»îЧ¹û¡£ ¡¡¡¡HBVÇÖÈë¸Îϸ°ûºó£¬²¿·ÖË«Á´»·×´HBV DNAÔÚϸ°ûºËÄÚÒÔ¸ºÁ´DNAΪģ°åÑÓ³¤ÕýÁ´ÒÔÐÞ²¹ÕýÁ´ÖеÄÁÑÏ¶Çø£¬Ðγɹ²¼Û±ÕºÏ»·×´DNA (cccDNA)£»È»ºóÒÔcccDNAΪģ°å£¬×ªÂ¼³É¼¸ÖÖ²»Í¬³¤¶ÈµÄmRNA£¬·Ö±ð×÷Ϊǰ»ùÒò×éRNAºÍ±àÂëHBVµÄ¸÷ÖÖ¿¹Ô¡£cccDNA°ëÊÙ (Ë¥) ÆÚ½Ï³¤£¬ºÜÄÑ´ÓÌåÄÚ³¹µ×Çå³ý[2, 3]¡£ ¡¡¡¡HBVÒÑ·¢ÏÖÓÐA~I 9¸ö»ùÒòÐÍ[4, 5]£¬ÔÚÎÒ¹úÒÔCÐͺÍBÐÍΪÖ÷¡£HBV»ùÒòÐͺͼ²²¡½øÕ¹ºÍ¸ÉÈÅËØ¦ÁÖÎÁÆÐ§¹ûÓйء£ÓëC»ùÒòÐ͸ÐȾÕßÏà±È£¬B»ùÒòÐ͸ÐȾÕß½ÏÔç³öÏÖHBeAgѪÇåѧת»»£¬½ÏÉÙ½øÕ¹ÎªÂýÐÔ¸ÎÑס¢¸ÎÓ²»¯ºÍÔ·¢ÐÔ¸Îϸ°û°©[6-9]£»²¢ÇÒHBeAgÑôÐÔ»¼Õß¶Ô¸ÉÈÅËØ¦ÁÖÎÁƵÄÓ¦´ðÂʸßÓÚC»ùÒòÐÍ£»A»ùÒòÐÍ»¼Õ߸ßÓÚD»ùÒòÐÍ [10-12]¡£ ¡¡¡¡¶þ¡¢ Á÷Ðв¡Ñ§ ¡¡¡¡HBV¸ÐȾ³ÊÊÀ½çÐÔÁ÷ÐУ¬µ«²»Í¬µØÇøHBV¸ÐȾµÄÁ÷ÐÐÇ¿¶È²îÒìºÜ´ó¡£¾ÝÊÀ½çÎÀÉú×éÖ¯±¨µÀ£¬È«ÇòÔ¼20ÒÚÈËÔø¸ÐȾ¹ýHBV£¬ÆäÖÐ3.5ÒÚÈËΪÂýÐÔHBV¸ÐȾÕߣ¬Ã¿ÄêÔ¼ÓÐ100ÍòÈËËÀÓÚHBV¸ÐȾËùÖµĸÎË¥½ß¡¢¸ÎÓ²»¯ºÍÔ·¢ÐÔ¸Îϸ°û°© (HCC)[13, 14]¡£ ¡¡¡¡2006ÄêÈ«¹úÒÒÐ͸ÎÑ×Á÷Ðв¡Ñ§µ÷²é±íÃ÷£¬ÎÒ¹ú1-59ËêÒ»°ãÈËȺHBsAgЯ´øÂÊΪ7.18%£¬ 5ËêÒÔ϶ùͯµÄHBsAg½öΪ0.96%[15, 16]¡£¾Ý´ËÍÆË㣬ÎÒ¹úÏÖÓеÄÂýÐÔHBV¸ÐȾÕßÔ¼9300ÍòÈË£¬ÆäÖÐÂýÐÔÒÒÐ͸ÎÑ×»¼ÕßÔ¼2000ÍòÀý[17]¡£ ¡¡¡¡HBVÊÇѪԴ´«²¥ÐÔ¼²²¡£¬Ö÷Òª¾Ñª£¨Èç²»°²È«×¢ÉäµÈ£©¡¢Ä¸Ó¤¼°ÐÔ½Ó´¥´«²¥[14]¡£ÓÉÓÚ¶ÔÏ×ѪԱʵʩÑϸñµÄHBsAgɸ²é£¬¾ÊäѪ»òÑªÒºÖÆÆ·ÒýÆðµÄHBV¸ÐȾÒѽÏÉÙ·¢Éú£»¾ÆÆËðµÄƤ·ôճĤ´«²¥Ö÷ÒªÊÇÓÉÓÚʹÓÃδ¾ÑϸñÏû¶¾µÄÒ½ÁÆÆ÷е¡¢ÇÖÈëÐÔÕïÁƲÙ×÷ºÍÊÖÊõ£¬²»°²È«×¢ÉäÌØ±ðÊÇ×¢É䶾ƷµÈ£»ÆäËûÈçÐÞ×ã¡¢ÎÆÉí¡¢Ôú¶ú»·¿×¡¢Ò½ÎñÈËÔ±¹¤×÷ÖеÄÒâÍⱩ¶¡¢¹²ÓÃÌêÐëµ¶ºÍÑÀË¢µÈÒ²¿É´«²¥ (¢ó)¡£Ä¸Ó¤´«²¥Ö÷Òª·¢ÉúÔÚΧÉú (²ú) ÆÚ£¬¶àΪÔÚ·ÖÃäʱ½Ó´¥HBVÑôÐÔĸÇ×µÄѪҺºÍÌåÒº´«²¥ (¢ñ)£¬Ëæ×ÅÒÒ¸ÎÒßÃçÁªºÏÒÒÐ͸ÎÑ×ÃâÒßÇòµ°°×µÄÓ¦Óã¬Ä¸Ó¤´«²¥ÒÑ´óΪ¼õÉÙ[18]¡£ÓëHBVÑôÐÔÕß·¢ÉúÎÞ·À»¤µÄÐÔ½Ó´¥£¬ÌرðÊÇÓжà¸öÐÔ°éÂÂÕߣ¬Æä¸ÐȾHBVµÄΣÏÕÐÔÔö¸ß (¢ñ)¡£ ¡¡¡¡HBV²»¾ºôÎüµÀºÍÏû»¯µÀ´«²¥£¬Òò´ËÈÕ³£Ñ§Ï°¡¢¹¤×÷»òÉú»î½Ó´¥£¬Èçͬһ°ì¹«ÊÒ¹¤×÷ (°üÀ¨¹²ÓüÆËã»úµÈ°ì¹«ÓÃÆ·)¡¢ÎÕÊÖ¡¢Óµ±§¡¢Í¬×¡Ò»ËÞÉᡢͬһ²ÍÌüÓòͺ͹²ÓòÞËùµÈÎÞѪҺ±©Â¶µÄ½Ó´¥£¬Ò»°ã²»»á´«È¾HBV¡£Á÷Ðв¡Ñ§ºÍʵÑéÑо¿Òàδ·¢ÏÖHBVÄܾÎüѪÀ¥³æ (Îᢳô³æµÈ) ´«²¥[19] ¡£ ¡¡¡¡Èý¡¢×ÔȻʷ ¡¡¡¡¸ÐȾʱµÄÄêÁäÊÇÓ°ÏìÂýÐÔ»¯µÄ×îÖ÷ÒªÒòËØ¡£ÔÚΧÉú (²ú) ÆÚºÍÓ¤Ó×¶ùʱÆÚ¸ÐȾHBVÕßÖУ¬·Ö±ðÓÐ90%ºÍ25%~30%½«·¢Õ¹³ÉÂýÐÔ¸ÐȾ£¬¶ø5ËêÒÔºó¸ÐȾÕß½öÓÐ5~10£¥·¢Õ¹ÎªÂýÐÔ¸ÐȾ[20] (¢ñ)¡£Ó¤Ó×¶ùÆÚHBV¸ÐȾµÄ×ÔȻʷһ°ã¿ÉÈËΪµØ»®·ÖΪ4¸öÆÚ£¬¼´ÃâÒßÄÍÊÜÆÚ¡¢ÃâÒßÇå³ýÆÚ¡¢·Ç»î¶¯»òµÍ£¨·Ç£©¸´ÖÆÆÚºÍÔٻÆÚ[[21]¡£ÃâÒßÄÍÊÜÆÚ£ºÆäÌØµãÊÇѪÇåHBsAgºÍHBeAgÑôÐÔ£¬ HBV DNAÔØÁ¿¸ß ( ³£³£ > 106 IU/mL£¬Ï൱ÓÚ107¿½±´/mL)£¬µ«ÑªÇå±û°±Ëá°±»ù×ªÒÆÃ¸ (ALT) ˮƽÕý³££¬¸Î×é֯ѧÎÞÃ÷ÏÔÒì³£²¢¿Éά³ÖÊýÄêÉõÖÁÊýÊ®Äê[22]£¬»òÇá¶ÈÑ×Ö¢»µËÀ¡¢ÎÞ»ò½öÓлºÂý¸ÎÏËά»¯µÄ½øÕ¹¡£ÃâÒßÇå³ýÆÚ£º±íÏÖΪѪÇåHBV DNAµÎ¶È > 2000 IU/mL£¨Ï൱ÓÚ104¿½±´/mL£©£¬°éÓÐALT³ÖÐø»ò¼äЪÉý¸ß£¬¸Î×é֯ѧÖжȻòÑÏÖØÑ×Ö¢»µËÀ¡¢¸ÎÏËά»¯¿É¿ìËÙ½øÕ¹£¬²¿·Ö»¼Õ߿ɷ¢Õ¹Îª¸ÎÓ²»¯ºÍ¸ÎË¥½ß¡£·Ç»î¶¯»òµÍ (·Ç) ¸´ÖÆÆÚ£º±íÏÖΪHBeAgÒõÐÔ¡¢¿¹-HBeÑôÐÔ£¬HBV DNA³ÖÐøµÍÓÚ2000 IU/mL£¨Ï൱ÓÚ104¿½±´/mL£©»ò¼ì²â²»³ö (PCR·¨)¡¢ALTˮƽÕý³££¬¸Î×é֯ѧÎÞÑ×Ö¢»ò½öÓÐÇá¶ÈÑ×Ö¢£»ÕâÊÇHBV¸ÐȾ»ñµÃÃâÒß¿ØÖƵĽá¹û£¬´ó²¿·Ö´ËÆÚ»¼Õß·¢Éú¸ÎÓ²»¯ºÍHCCµÄ·çÏÕ´ó´ó¼õÉÙ£¬ÔÚһЩ³ÖÐøHBV DNAתÒõÊýÄêµÄ»¼Õߣ¬×Ô·¢ÐÔHBsAgѪÇåѧת»»ÂÊΪ1~3%£¯Äê¡£ÔٻÆÚ£º²¿·Ö´¦ÓڷǻÆÚµÄ»¼Õß¿ÉÄܳöÏÖ1´Î»òÊý´ÎµÄ¸ÎÑ×·¢×÷£¬¶àÊý±íÏÖΪHBeAgÒõÐÔ¡¢¿¹-HBeÑôÐÔ£¨²¿·ÖÊÇÓÉÓÚǰCÇøÓ룯»òBCP±äÒìËùµ¼ÖÂHBeAg±í´ïˮƽµÍÏ»ò²»±í´ï£©£¬µ«ÈÔÓÐHBV DNA»î¶¯ÐÔ¸´ÖÆ¡¢ALT³ÖÐø»ò·´¸´Òì³££¬³ÉΪHBeAgÒõÐÔÂýÐÔÒÒÐ͸ÎÑ×[23]£¬ÕâЩ»¼Õ߿ɽøÕ¹Îª¸ÎÏËά»¯¡¢¸ÎÓ²»¯¡¢Ê§´ú³¥¸ÎÓ²»¯ºÍHCC£»Ò²Óв¿·Ö»¼Õ߿ɳö¬F×Ô·¢ÐÔHBsAgÏûʧ£¨°é»ò²»°é¿¹-HBs£©ºÍHBV DNA½µµÍ»ò¼ì²â²»µ½£¬Òò¶øÔ¤ºó³£Á¼ºÃ¡£ÉÙ²¿·Ö´ËÆÚ»¼Õ߿ɻظ´µ½HBeAgÑôÐÔµÄ״̬£¨ÌرðÊÇÔÚÃâÒßÒÖÖÆ×´Ì¬Èç½ÓÊÜ»¯ÁÆÊ±£©¡£ ¡¡¡¡²¢²»ÊÇËùÓиÐȾHBVÕß¶¼¾¹ýÒÔÉÏËĸöÆÚ¡£ÐÂÉú¶ùʱÆÚ¸ÐȾHBV£¬½öÉÙÊý£¨Ô¼5£¥£©¿É×Ô·¢Çå³ýHBV£¬¶ø¶àÊýÓнϳ¤µÄÃâÒßÄÍÆÚ£¬È»ºó½øÈëÃâÒßÇå³ýÆÚ¡£µ«ÇàÉÙÄêºÍ³ÉÄêʱÆÚ¸ÐȾHBV£¬¶àÎÞÃâÒßÄÍÊÜÆÚ£¬¶øÖ±½Ó½øÈëÃâÒßÇå³ýÆÚ£¬ËûÃÇÖеĴ󲿷ֿÉ×Ô·¢Çå³ýHBV£¨Ô¼90£¥~95£¥£©£¬ÉÙÊý£¨Ô¼5£¥~10£¥£©·¢Õ¹ÎªHBeAgÑôÐÔÂýÐÔÒÒÐ͸ÎÑס£ ¡¡¡¡×Ô·¢ÐÔHBeAgѪÇåѧת»»Ö÷Òª³öÏÖÔÚÃâÒßÇå³ýÆÚ£¬Äê·¢ÉúÂÊԼΪ2%~15%£¬ÆäÖÐÄêÁäСÓÚ40Ëê¡¢ALTÉý¸ßÒÔ¼°¸ÐȾHBV»ùÒòAÐͺÍBÐÍÕß·¢ÉúÂʽϸß[21, 24]¡£HBeAgѪÇåѧת»»ºóÿÄê´óÔ¼ÓÐ0.5%~1.0%·¢ÉúHBsAgÇå³ý[25]¡£ ¡¡¡¡ÂýÐÔHBV¸ÐȾÕߵĸÎÓ²»¯·¢ÉúÂÊÓë¸ÐȾ״̬Óйء£ÃâÒßÄÍÊÜÆÚ»¼ÕßÖ»ÓкÜÇá»òûÓиÎÏËά»¯½øÕ¹£¬¶øÃâÒßÇå³ýÆÚÊǸÎÓ²»¯µÄ¸ß·¢Ê±ÆÚ¡£¸ÎÓ²»¯µÄÀÛ»ý·¢ÉúÂÊÓë³ÖÐø¸ß²¡¶¾ÔØÁ¿³ÊÕýÏà¹Ø£¬HBV DNAÊǶÀÁ¢ÓÚHBeAgºÍALTÒÔÍâÄܹ»¶ÀÁ¢Ô¤²â¸ÎÓ²»¯·¢ÉúµÄΣÏÕÒòËØ¡£·¢Éú¸ÎÓ²»¯µÄ¸ßΣÒòËØ»¹°üÀ¨ÊȾơ¢ºÏ²¢HCV¡¢HDV»òHIV¸ÐȾµÈ[26-28] (I)¡£ ¡¡¡¡·Ç¸ÎÓ²»¯µÄ»¼Õß½ÏÉÙ·¢ÉúÓÚÔ·¢ÐÔ¸Îϸ°û¸Î°©£¨HCC£©¡£¸ÎÓ²»¯»¼ÕßÖÐÆäÄê·¢ÉúÂÊΪ3%~6%[29-31]¡£HBeAgÑôÐÔºÍ/»òHBV DNA > 2,000 IU/mL£¨Ï൱ÓÚ104¿½±´/mL£©ÊǸÎÓ²»¯ºÍHCC·¢ÉúµÄÏÔÖøÎ£ÏÕÒòËØ[8, 32-35]¡£´óÑù±¾Ñо¿ÏÔʾ£¬ÄêÁä´ó¡¢ÄÐÐÔ¡¢ALTˮƽ¸ßÒ²ÊǸÎÓ²»¯ºÍHCC·¢ÉúµÄΣÏÕÒòËØ[25, 33]¡£HCC¼Ò×åÊ·Ò²ÊÇÏà¹ØÒòËØ£¬µ«ÔÚͬÑùµÄÒÅ´«±³¾°Ï£¬HBV²¡¶¾ÔØÁ¿¸üÎªÖØÒª[36] (¢ò-3)¡£ ¡¡¡¡ËÄ¡¢Ô¤·À ¡¡¡¡£¨Ò»£©ÒÒÐ͸ÎÑ×ÒßÃçÔ¤·À ¡¡¡¡½ÓÖÖÒÒÐ͸ÎÑ×ÒßÃçÊÇÔ¤·ÀHBV¸ÐȾµÄ×îÓÐЧ·½·¨¡£ÒÒÐ͸ÎÑ×ÒßÃçµÄ½ÓÖÖ¶ÔÏóÖ÷ÒªÊÇÐÂÉú¶ù[37]£¬Æä´ÎΪӤÓ×¶ù£¬15ËêÒÔÏÂδÃâÒßÈËȺºÍ¸ßΣÈËȺ (ÈçÒ½ÎñÈËÔ±¡¢¾³£½Ó´¥ÑªÒºµÄÈËÔ±¡¢ÍÐÓ×»ú¹¹¹¤×÷ÈËÔ±¡¢Æ÷¹ÙÒÆÖ²»¼Õß¡¢¾³£½ÓÊÜÊäѪ»òÑªÒºÖÆÆ·Õß¡¢ÃâÒß¹¦ÄܵÍÏÂÕß¡¢Ò×·¢ÉúÍâÉËÕß¡¢HBsAgÑôÐÔÕߵļÒÍ¥³ÉÔ±¡¢ÄÐÐÔͬÐÔÁµ»òÓжà¸öÐÔ°éº;²ÂöÄÚ×¢É䶾ƷÕßµÈ)¡£ÒÒÐ͸ÎÑ×ÒßÃçÈ«³ÌÐè½ÓÖÖ3Õ룬°´ÕÕ0¡¢1¡¢6¸öÔ³ÌÐò£¬¼´½ÓÖÖµÚ1ÕëÒßÃçºó£¬¼ä¸ô1¸öÔ¼°6¸öÔÂ×¢ÉäµÚ2¼°µÚ3ÕëÒßÃç¡£ÐÂÉú¶ù½ÓÖÖÒÒÐ͸ÎÑ×ÒßÃçÒªÇóÔÚ³öÉúºó24 hÄÚ½ÓÖÖ£¬Ô½ÔçÔ½ºÃ¡£½ÓÖÖ²¿Î»ÐÂÉú¶ùΪÍÎǰ²¿Íâ²à¼¡ÈâÄÚ£¬¶ùͯºÍ³ÉÈËΪÉϱÛÈý½Ç¼¡Öв¿¼¡ÈâÄÚ×¢Éä¡£ ¡¡¡¡µ¥ÓÃÒÒÐ͸ÎÑ×ÒßÃç×è¶ÏĸӤ´«²¥µÄ×è¶ÏÂÊΪ87.8%[38] (¢ò-3)¡£¶ÔHBsAgÑôÐÔĸÇ×µÄÐÂÉú¶ù£¬Ó¦ÔÚ³öÉúºó24 hÄÚ¾¡Ô磨×îºÃÔÚ³öÉúºó12 h£©×¢ÉäÒÒÐ͸ÎÑ×ÃâÒßÇòµ°°× (HBIG)£¬¼ÁÁ¿Ó¦¡Ý100 IU£¬Í¬Ê±ÔÚ²»Í¬²¿Î»½ÓÖÖ10 ¦ÌgÖØ×é½Íĸ»ò20¦ÌgÖйú²ÖÊóÂÑĸϸ°û (CHO) ÒÒÐ͸ÎÑ×ÒßÃ磬ÔÚ1¸öÔºÍ6¸öÔÂʱ·Ö±ð½ÓÖÖµÚ2ºÍµÚ3ÕëÒÒÐ͸ÎÑ×ÒßÃ磬¿ÉÏÔÖøÌá¸ß×è¶ÏĸӤ´«²¥µÄЧ¹û[37, 38] (¢ò-3)¡£Ò²¿ÉÔÚ³öÉúºó12 hÄÚÏÈ×¢Éä1ÕëHBIG£¬1¸öÔºóÔÙ×¢ÉäµÚ2ÕëHBIG£¬²¢Í¬Ê±ÔÚ²»Í¬²¿Î»½ÓÖÖÒ»Õë10 ¦ÌgÖØ×é½Íĸ»ò20¦Ìg CHOÒÒÐ͸ÎÑ×ÒßÃ磬¼ä¸ô1ºÍ6¸öÔ·ֱð½ÓÖÖµÚ2ºÍµÚ3ÕëÒÒÐ͸ÎÑ×ÒßÃç[39]¡£ÐÂÉú¶ùÔÚ³öÉú12 hÄÚ×¢ÉäHBIGºÍÒÒÐ͸ÎÑ×ÒßÃçºó£¬¿É½ÓÊÜHBsAgÑôÐÔĸÇ׵IJ¸Èé[40, 41] (III)¡£ ¡¡¡¡¶ÔHBsAgÒõÐÔĸÇ×µÄÐÂÉú¶ù¿ÉÓÃ5¦Ìg»ò10¦Ìg½Íĸ»ò10¦Ìg CHOÒÒÐ͸ÎÑ×ÒßÃçÃâÒߣ»¶ÔÐÂÉú¶ùʱÆÚδ½ÓÖÖÒÒÐ͸ÎÑ×ÒßÃçµÄ¶ùͯӦ½øÐв¹ÖÖ£¬¼ÁÁ¿Îª5¦Ìg»ò10¦ÌgÖØ×é½Íĸ»ò10¦Ìg CHOÒÒÐ͸ÎÑ×ÒßÃ磻¶Ô³ÉÈ˽¨Òé½ÓÖÖ20¦Ìg½Íĸ»ò20¦Ìg CHOÒÒÐ͸ÎÑ×ÒßÃç¡£¶ÔÃâÒß¹¦ÄܵÍÏ»òÎÞÓ¦´ðÕߣ¬Ó¦Ôö¼ÓÒßÃçµÄ½ÓÖÖ¼ÁÁ¿£¨Èç60¦Ìg£©ºÍÕë´Î£»¶Ô3ÕëÃâÒß³ÌÐòÎÞÓ¦´ðÕß¿ÉÔÙ½ÓÖÖ3Õ룬²¢ÓÚµÚ2´Î½ÓÖÖ3ÕëÒÒÐ͸ÎÑ×ÒßÃçºó1~2¸öÔ¼ì²âѪÇåÖп¹-HBs£¬ÈçÈÔÎÞÓ¦´ð£¬¿É½ÓÖÖÒ»Õë60¦ÌgÖØ×é½ÍĸÒÒÐ͸ÎÑ×ÒßÃç¡£ ¡¡¡¡½ÓÖÖÒÒÐ͸ÎÑ×ÒßÃçºóÓп¹ÌåÓ¦´ðÕߵı£»¤Ð§¹ûÒ»°ãÖÁÉٿɳÖÐø12Äê[42]£¬Òò´Ë£¬Ò»°ãÈËȺ²»ÐèÒª½øÐп¹-HBs¼à²â»ò¼ÓÇ¿ÃâÒß¡£µ«¶Ô¸ßΣÈËȺ¿É½øÐп¹-HBs¼à²â£¬È翹-HBs<10 mIU/mL£¬¿É¸øÓè¼ÓÇ¿ÃâÒß[43](¢ó)¡£ ¡¡¡¡(¶þ) Çжϴ«²¥Í¾¾ ¡¡¡¡´óÁ¦Íƹ㰲ȫעÉä (°üÀ¨Õë¾ÄµÄÕë¾ß)£¬²¢Ñϸñ×ñÑÒ½Ôº¸ÐȾ¹ÜÀíÖеıê×¼·À»¤£¨Standard Precaution£©ÔÔò¡£·þÎñÐÐÒµËùÓõÄÀí·¢¡¢¹ÎÁ³¡¢Ð޽𢴩´ÌºÍÎÆÉíµÈÆ÷¾ßÒ²Ó¦ÑϸñÏû¶¾¡£×¢Òâ¸öÈËÎÀÉú£¬²»ºÍÈκÎÈ˹²ÓÃÌêÐëµ¶ºÍÑÀ¾ßµÈÓÃÆ·¡£½øÐÐÕýÈ·µÄÐÔ½ÌÓý£¬ÈôÐÔ°éÂÂΪHBsAgÑôÐÔÕߣ¬Ó¦½ÓÖÖÒÒÐ͸ÎÑ×ÒßÃç»ò²ÉÓð²È«Ì×£»ÔÚÐÔ»ï°é½¡¿µ×´¿ö²»Ã÷µÄÇé¿öÏ£¬Ò»¶¨ÒªÊ¹Óð²È«Ì×ÒÔÔ¤·ÀÒÒÐ͸ÎÑ×¼°ÆäËûѪԴÐÔ»òÐÔ´«²¥¼²²¡¡£¶ÔHBsAgÑôÐÔµÄÔи¾£¬Ó¦±ÜÃâÑòĤǻ´©´Ì£¬²¢Ëõ¶Ì·ÖÃäʱ¼ä£¬±£Ö¤Ì¥Å̵ÄÍêÕûÐÔ£¬¾¡Á¿¼õÉÙÐÂÉú¶ù±©Â¶ÓÚĸѪµÄ»ú»á¡£ ¡¡¡¡(Èý)ÒâÍⱩ¶ºóHBVÔ¤·À[44] ¡¡¡¡ÔÚÒâÍâ½Ó´¥HBV¸ÐȾÕßµÄѪҺºÍÌåÒººó£¬¿É°´ÕÕÒÔÏ·½·¨´¦Àí£º ¡¡¡¡1£®ÑªÇåѧ¼ì²â Ó¦Á¢¼´¼ì²âHBV DNA¡¢HBsAg¡¢¿¹-HBs¡¢HBeAg¡¢¿¹-HBc¡¢ALTºÍAST£¬²¢ÔÚ3ºÍ6¸öÔÂÄÚ¸´²é¡£ ¡¡¡¡2£®Ö÷¶¯ºÍ±»¶¯ÃâÒß ÈçÒѽÓÖÖ¹ýÒÒÐ͸ÎÑ×ÒßÃ磬ÇÒÒÑÖª¿¹-HBs ¡Ý10 mIU/mLÕߣ¬¿É²»½øÐÐÌØÊâ´¦Àí¡£Èçδ½ÓÖÖ¹ýÒÒÐ͸ÎÑ×ÒßÃ磬»òËä½ÓÖÖ¹ýÒÒÐ͸ÎÑ×ÒßÃ磬µ«¿¹-HBs <10 mIU/mL»ò¿¹-HBsˮƽ²»Ï꣬ӦÁ¢¼´×¢ÉäHBIG 200~400 IU£¬²¢Í¬Ê±ÔÚ²»Í¬²¿Î»½ÓÖÖÒ»ÕëÒÒÐ͸ÎÑ×ÒßÃç (20mg)£¬ÓÚ1ºÍ6¸öÔºó·Ö±ð½ÓÖÖµÚ2ºÍµÚ3ÕëÒÒÐ͸ÎÑ×ÒßÃç (¸÷20 mg)¡£ ¡¡¡¡(ËÄ) ¶Ô»¼ÕߺÍЯ´øÕߵĹÜÀí ¡¡¡¡ÔÚÕï¶Ï³ö¼±ÐÔ»òÂýÐÔÒÒÐ͸ÎÑ×ʱ£¬Ó¦°´¹æ¶¨Ïòµ±µØ¼²²¡Ô¤·À¿ØÖÆÖÐÐı¨¸æ£¬²¢½¨Òé¶Ô»¼ÕߵļÒÍ¥³ÉÔ±½øÐÐѪÇåHBsAg¡¢¿¹-HBcºÍ¿¹-HBs¼ì²â£¬²¢¶ÔÆäÖеÄÒ׸ÐÕß (¸Ã3ÖÖ±êÖ¾Îï¾ùÒõÐÔÕß) ½ÓÖÖÒÒÐ͸ÎÑ×ÒßÃç¡£ ¡¡¡¡ÒÒÐ͸ÎÑ×»¼ÕߺÍЯ´øÕߵĴ«È¾ÐԸߵͣ¬Ö÷Ҫȡ¾öÓÚѪҺÖÐHBV DNAˮƽ£¬¶øÓëѪÇåALT¡¢AST»òµ¨ºìËØË®Æ½Î޹ء£¶ÔÒÒÐ͸ÎÑ×»¼ÕߺÍЯ´øÕßµÄËæ·Ã¼û±¾¡¶Ö¸ÄÏ¡·¡°»¼ÕßµÄËæ·Ã¡±¡£ ¡¡¡¡¶ÔÂýÐÔHBVЯ´øÕß¼°HBsAgЯ´øÕß (¼û±¾¡¶Ö¸ÄÏ¡·¡°ÁÙ´²Õï¶Ï¡±)£¬ ³ý²»ÄܾèÏ×ѪҺ¡¢×éÖ¯Æ÷¹Ù¼°´Óʹú¼ÒÃ÷ÎĹ涨µÄÖ°Òµ»ò¹¤ÖÖÍ⣬¿ÉÕÕ³£¹¤×÷ºÍѧϰ£¬µ«Ó¦¶¨ÆÚ½øÐÐÒ½Ñ§Ëæ·Ã¡£ ¡¡¡¡Îå¡¢ÁÙ´²Õï¶Ï ¡¡¡¡¼ÈÍùÓÐÒÒÐ͸ÎÑײ¡Ê·»òHBsAgÑôÐÔ³¬¹ý6¸öÔ£¬ÏÖHBsAgºÍ£¨»ò£©HBV DNAÈÔΪÑôÐÔÕߣ¬¿ÉÕï¶ÏΪÂýÐÔHBV¸ÐȾ¡£¸ù¾ÝHBV¸ÐȾÕßµÄѪÇåѧ¡¢²¡¶¾Ñ§¡¢ÉúÎﻯѧÊÔÑé¼°ÆäËûÁÙ´²ºÍ¸¨Öú¼ì²é½á¹û£¬¿É½«ÂýÐÔHBV¸ÐȾ·ÖΪ£º ¡¡¡¡£¨Ò»£©ÂýÐÔÒÒÐ͸ÎÑ× ¡¡¡¡1£®HBeAgÑôÐÔÂýÐÔÒÒÐ͸ÎÑ× ÑªÇåHBsAg¡¢HBeAgÑôÐÔ¡¢¿¹-HBeÒõÐÔ£¬HBV DNAÑôÐÔ£¬ALT³ÖÐø»ò·´¸´Éý¸ß£¬»ò¸Î×é֯ѧ¼ì²éÓиÎÑײ¡±ä¡£ ¡¡¡¡2£®HBeAgÒõÐÔÂýÐÔÒÒÐ͸ÎÑ× ÑªÇåHBsAgÑôÐÔ£¬HBeAg³ÖÐøÒõÐÔ£¬¿¹-HBeÑôÐÔ»òÒõÐÔ£¬ HBV DNAÑôÐÔ£¬ALT³ÖÐø»ò·´¸´Òì³££¬»ò¸Î×é֯ѧ¼ì²éÓиÎÑײ¡±ä¡£ ¡¡¡¡¸ù¾ÝÉúÎﻯѧÊÔÑé¼°ÆäËûÁÙ´²ºÍ¸¨Öú¼ì²é½á¹û£¬ÉÏÊöÁ½ÐÍÂýÐÔÒÒÐ͸ÎÑ×Ò²¿É½øÒ»²½·ÖΪÇá¶È¡¢ÖжȺÍÖØ¶È[45]¡£ ¡¡¡¡£¨¶þ£©ÒÒÐ͸ÎÑ׸ÎÓ²»¯ ¡¡¡¡ÒÒÐ͸ÎÑ׸ÎÓ²»¯ÊÇÂýÐÔÒÒÐ͸ÎÑ×·¢Õ¹µÄ½á¹û£¬Æä²¡Àíѧ¶¨ÒåΪÃÖÂþÐÔÏËά»¯°éÓмÙСҶÐγɡ£ ¡¡¡¡1£®´ú³¥ÆÚ¸ÎÓ²»¯ Ò»°ãÊôChild-Pugh A¼¶¡£Ó°Ïñѧ¡¢Éú»¯Ñ§»òѪҺѧ¼ì²éÓиÎϸ°ûºÏ³É¹¦ÄÜÕϰ»òÞ²Âö¸ßѹ֢£¨ÈçÆ¢¹¦ÄÜ¿º½ø¼°Ê³¹Üθµ×¾²ÂöÇúÕÅ£©Ö¤¾Ý£¬»ò×é֯ѧ·ûºÏ¸ÎÓ²»¯Õï¶Ï£¬µ«ÎÞʳ¹Üθµ×¾²ÂöÇúÕÅÆÆÁѳöѪ¡¢¸¹Ë®»ò¸ÎÐÔÄÔ²¡µÈÑÏÖØ²¢·¢Ö¢¡£ ¡¡¡¡2£®Ê§´ú³¥ÆÚ¸ÎÓ²»¯ Ò»°ãÊôChild-Pugh B¡¢C¼¶¡£»¼ÕßÒÑ·¢Éúʳ¹Üθµ×¾²ÂöÇúÕÅÆÆÁѳöѪ¡¢¸ÎÐÔÄÔ²¡¡¢¸¹Ë®µÈÑÏÖØ²¢·¢Ö¢¡£ ¡¡¡¡Òà¿É½«´ú³¥ÆÚºÍʧ´ú³¥ÆÚ¸ÎÓ²»¯ÔÙ·ÖΪ»î¶¯ÆÚ»ò¾²Ö¹ÆÚ[45]¡£ ¡¡¡¡£¨Èý£©Ð¯´øÕß ¡¡¡¡1£®ÂýÐÔHBVЯ´øÕß ¶àΪ´¦ÓÚÃâÒßÄÍÊÜÆÚµÄHBsAg¡¢HBeAgºÍHBV DNAÑôÐÔÕߣ¬bb1ÄêÄÚÁ¬ÐøËæ·Ã3´ÎÒÔÉϾùÏÔʾѪÇåALTºÍASTÔÚÕý³£·¶Î§£¬¸Î×é֯ѧ¼ì²éÎÞÃ÷ÏÔÒì³£¡£ ¡¡¡¡2£®·Ç»î¶¯ÐÔHBsAgЯ´øÕß ÑªÇåHBsAgÑôÐÔ¡¢HBeAgÒõÐÔ¡¢¿¹-HBeÑôÐÔ»òÒõÐÔ£¬HBV DNAµÍÓÚ×îµÍ¼ì²âÏÞ£¬1ÄêÄÚÁ¬ÐøËæ·Ã3´ÎÒÔÉÏ£¬ALT¾ùÔÚÕý³£·¶Î§¡£¸Î×é֯ѧ¼ì²éÏÔʾ£ºKnodell ¸ÎÑ׻ָÊý£¨HAI£©< 4»ò¸ù¾ÝÆäËûµÄ°ë¶¨Á¿¼Æ·ÖϵͳÅж¨²¡±äÇá΢¡£ ¡¡¡¡£¨ËÄ£©ÒþÄäÐÔÂýÐÔÒÒÐ͸ÎÑ× ¡¡¡¡ÑªÇåHBsAgÒõÐÔ£¬µ«ÑªÇåºÍ£¨»ò£©¸Î×éÖ¯ÖÐHBV DNAÑôÐÔ£¬²¢ÓÐÂýÐÔÒÒÐ͸ÎÑ×µÄÁÙ´²±íÏÖ¡£³ýHBV DNAÑôÐÔÍ⣬»¼Õß¿ÉÓÐѪÇ忹-HBs¡¢¿¹-HBeºÍ£¨»ò£©¿¹-HBcÑôÐÔ£¬µ«Ô¼20%ÒþÄäÐÔÂýÐÔÒÒÐ͸ÎÑ×»¼ÕßµÄѪÇåѧ±êÖ¾¾ùΪÒõÐÔ¡£Õï¶ÏÐèÅųýÆäËû²¡¶¾¼°·Ç²¡¶¾ÒòËØÒýÆðµÄ¸ÎËðÉË¡£ ¡¡¡¡Áù¡¢ÊµÑéÊÒ¼ì²é ¡¡¡¡£¨Ò»£©ÉúÎﻯѧ¼ì²é ¡¡¡¡1£®ÑªÇåALTºÍAST ѪÇåALTºÍASTˮƽһ°ã¿É·´Ó³¸Îϸ°ûËðÉ˳̶ȣ¬×îΪ³£Óᣠ¡¡¡¡2£®ÑªÇ嵨ºìËØ ͨ³£ÑªÇ嵨ºìËØË®Æ½Óë¸Îϸ°û»µËÀ³Ì¶ÈÓйأ¬µ«ÐèÓë¸ÎÄں͸ÎÍ⵨ÖÓÙ»ýËùÒýÆðµÄµ¨ºìËØÉý¸ß¼ø±ð¡£¸ÎË¥½ß»¼ÕßѪÇ嵨ºìËØ¿É³Ê½øÐÐÐÔÉý¸ß£¬Ã¿ÌìÉÏÉý ¡Ý 1±¶Õý³£ÖµÉÏÏÞ£¨ULN£©£¬¿É ¡Ý 10¡ÁULN£»Ò²¿É³öÏÖµ¨ºìËØÓëALTºÍAST·ÖÀëÏÖÏó¡£ ¡¡¡¡3£®ÑªÇå°×µ°°× ·´Ó³¸ÎÔàºÏ³É¹¦ÄÜ£¬ÂýÐÔÒÒÐ͸ÎÑס¢¸ÎÓ²»¯ºÍ¸ÎË¥½ß»¼Õß¿ÉÓÐѪÇå°×µ°°×Ͻµ¡£ ¡¡¡¡4£®ÄýѪøÔʱ¼ä£¨PT£©¼° PTA PTÊÇ·´Ó³¸ÎÔàÄýѪÒò×Ӻϳɹ¦ÄܵÄÖØÒªÖ¸±ê£¬ PTAÊÇPT²â¶¨ÖµµÄ³£Óñíʾ·½·¨£¬¶ÔÅжϼ²²¡½øÕ¹¼°Ô¤ºóÓнϴó¼ÛÖµ£¬½üÆÚÄÚPTA½øÐÐÐÔ½µÖÁ40%ÒÔÏÂΪ¸ÎË¥½ßµÄÖØÒªÕï¶Ï±ê×¼Ö®Ò»£¬< 20%ÕßÌáʾԤºó²»Á¼¡£ÒàÓвÉÓùú¼Ê±ê×¼»¯±ÈÖµ£¨INR£©À´±íʾ´ËÏîÖ¸±êÕߣ¬INRÖµÉý¸ßÓëPTAֵϽµÒâÒåÏàͬ¡£ ¡¡¡¡5£®µ¨¼îõ¥Ã¸ ¿É·´Ó³¸ÎÔàºÏ³É¹¦ÄÜ£¬¶ÔÁ˽ⲡÇéÇáÖØºÍ¼à²â¸Î²¡·¢Õ¹Óвο¼¼ÛÖµ¡£ ¡¡¡¡6£®¼×Ì¥µ°°×£¨AFP£© AFPÃ÷ÏÔÉý¸ßÖ÷Òª¼ûÓÚHCC£¬µ«Ò²¿ÉÌáʾ´óÁ¿¸Îϸ°û»µËÀºóµÄ¸Îϸ°ûÔÙÉú£¬¹ÊӦעÒâAFPÉý¸ßµÄ·ù¶È¡¢¶¯Ì¬±ä»¯¼°ÆäÓëALT¡¢ASTµÄÏû³¤¹ØÏµ£¬²¢½áºÏ»¼ÕßµÄÁÙ´²±íÏֺ͸ÎÔ೬ÉùÏÔÏñµÈÓ°Ïñѧ¼ì²é½á¹û½øÐÐ×ۺϷÖÎö¡£ ¡¡¡¡£¨¶þ£©HBVѪÇåѧ¼ì²â ¡¡¡¡HBVѪÇåѧ±êÖ¾°üÀ¨HBsAg¡¢¿¹-HBs¡¢HBeAg¡¢¿¹-HBe¡¢¿¹-HBcºÍ¿¹-HBc-IgM¡£HBsAgÑôÐÔ±íʾHBV¸ÐȾ£»¿¹-HBsΪ±£»¤ÐÔ¿¹Ì壬ÆäÑôÐÔ±íʾ¶ÔHBVÓÐÃâÒßÁ¦£¬¼ûÓÚÒÒÐ͸ÎÑ׿µ¸´¼°½ÓÖÖÒÒÐ͸ÎÑ×ÒßÃçÕߣ»HBsAgתÒõÇÒ¿¹-HBsתÑô£¬³ÆÎªHBsAgѪÇåѧת»»£» HBeAgתÒõÇÒ¿¹-HBeתÑô£¬³ÆÎªHBeAgѪÇåѧת»»£»¿¹-HBc-IgMÑôÐÔÌáʾHBV¸´ÖÆ£¬¶à¼ûÓÚÒÒÐ͸ÎÑ×¼±ÐÔÆÚ£¬µ«Òà¿É¼ûÓÚÂýÐÔÒÒÐ͸ÎÑ×¼±ÐÔ·¢×÷£»¿¹-HBc ×Ü¿¹ÌåÖ÷ÒªÊÇ¿¹-HBc-IgG, Ö»Òª¸ÐȾ¹ýHBV£¬ÎÞÂÛ²¡¶¾ÊÇ·ñ±»Çå³ý£¬´Ë¿¹Ìå¶àΪÑôÐÔ¡£ ¡¡¡¡ÎªÁ˽âÓÐÎÞHBVÓëHDVͬʱ»òÖØµþ¸ÐȾ£¬¿É²â¶¨HDAg¡¢¿¹-HDV¡¢¿¹-HDV IgMºÍHDV RNA¡£ ¡¡¡¡£¨Èý£©HBV DNA¡¢»ùÒòÐͺͱäÒì¼ì²â ¡¡¡¡1£®HBV DNA¶¨Á¿¼ì²â ¿É·´Ó³²¡¶¾¸´ÖÆË®Æ½£¬Ö÷ÒªÓÃÓÚÂýÐÔHBV¸ÐȾµÄÕï¶Ï¡¢ÖÎÁÆÊÊÓ¦Ö¤µÄÑ¡Ôñ¼°¿¹²¡¶¾ÁÆÐ§µÄÅжϡ£HBV DNAµÄ¼ì²âÖµ¿ÉÒÔ¹ú¼Êµ¥Î»£¨IU£©/mL»ò¿½±´/mL±íʾ£¬¸ù¾Ý¼ì²â·½·¨µÄ²»Í¬£¬1 IUÏ൱ÓÚ5.6¿½±´[46]¡£ ¡¡¡¡2£®HBV»ùÒò·ÖÐͺÍÄÍÒ©Í»±äÖê¼ì²â ³£Óõķ½·¨ÓУº£¨1£©»ùÒòÐÍÌØÒìÐÔÒýÎïPCR·¨£»£¨2£©ÏÞÖÆÐÔÆ¬¶Î³¤¶È¶à̬ÐÔ·ÖÎö·¨£¨RFLP£©£»£¨3£©ÏßÐÔ̽Õë·´ÏòÔÓ½»·¨£¨INNO-LiPA£©£»£¨4£©»ùÒòÐòÁвⶨ·¨µÈ¡£ ¡¡¡¡Æß¡¢Ó°ÏñѧÕï¶Ï ¡¡¡¡¿É¶Ô¸ÎÔà¡¢µ¨ÄÒ¡¢Æ¢Ôà½øÐг¬ÉùÏÔÏñ¡¢µç×Ó¼ÆËã»ú¶Ï²ãɨÃ裨CT£©ºÍ´Å¹²Õñ³ÉÏñ£¨MRI£©µÈ¼ì²é¡£Ó°Ïñѧ¼ì²éµÄÖ÷ҪĿµÄÊǼà²âÂýÐÔÒÒÐ͸ÎÑ×µÄÁÙ´²½øÕ¹¡¢Á˽âÓÐÎÞ¸ÎÓ²»¯¡¢·¢Ïֺͼø±ðռλÐÔ²¡±äÐÔÖÊ£¬ÓÈÆäÊÇɸ²éºÍÕï¶ÏHCC¡£ ¡¡¡¡¸ÎÔ൯ÐԲⶨ£¨hepatic elastography£©µÄÓÅÊÆÔÚÓÚÎÞ´´ÉËÐÔ¡¢²Ù×÷¼ò±ã¡¢¿ÉÖØ¸´ÐԺã¬Äܹ»±È½Ï׼ȷµØÊ¶±ð³öÇá¶È¸ÎÏËά»¯ºÍÖØ¶È¸ÎÏËά»¯£¯ÔçÆÚ¸ÎÓ²»¯[47, 48]¡£µ«Æä²â¶¨³É¹¦ÂÊÊÜ·ÊÅÖ¡¢Àß¼ä϶´óСµÈÒòËØÓ°Ï죬Æä²â¶¨ÖµÊܸÎÔàÖ¬·¾±ä¡¢Ñ×Ö¢»µËÀ¼°µ¨ÖÓÙ»ýµÄÓ°Ï죬ÇÒ²»Ò××¼È·Çø·ÖÏàÁÚµÄÁ½¼¶¸ÎÏËά»¯¡£ ¡¡¡¡°Ë¡¢²¡ÀíѧÕï¶Ï ¡¡¡¡¸Î×éÖ¯»î¼ìµÄÄ¿µÄÊÇÆÀ¹ÀÂýÐÔÒÒÐ͸ÎÑ×»¼Õ߸ÎÔಡ±ä³Ì¶È¡¢ÅųýÆäËû¸ÎÔ༲²¡¡¢ÅжÏÔ¤ºóºÍ¼à²âÖÎÁÆÓ¦´ð¡£ ¡¡¡¡ÂýÐÔÒÒÐ͸ÎÑ׵IJ¡ÀíÑ§ÌØµãÊÇÃ÷ÏԵĻã¹ÜÇø¼°ÆäÖÜΧÑ×Ö¢£¬½þÈóµÄÑ×֢ϸ°ûÖ÷ҪΪÁܰÍϸ°û£¬ÉÙÊýΪ½¬Ï¸°ûºÍ¾ÞÊÉϸ°û£»Ñ×֢ϸ°û¾Û¼¯³£ÒýÆð»ã¹ÜÇøÀ©´ó£¬²¢¿ÉÆÆ»µ½ç°åÒýÆð½çÃæ¸ÎÑ×£¨interface hepatitis£©£¬ÓÖ³ÆËéмÑù»µËÀ£¨piecemeal necrosis£©¡£Òà¿É¼ûСҶÄÚ¸Îϸ°û±äÐÔ¡¢»µËÀ£¬°üÀ¨ÈÚºÏÐÔ»µËÀºÍÇÅÐλµËÀµÈ£¬Ë没±ä¼ÓÖØ¶øÈÕÇ÷ÏÔÖø¡£¸ÎÔàÑ×Ö¢»µËÀ¿Éµ¼Ö¸ÎÄÚ½ºÔ¹ý¶È³Á»ý£¬ÐγÉÏËά¼ä¸ô¡£È粡±ä½øÒ»²½¼ÓÖØ£¬¿ÉÒýÆð¸ÎСҶ½á¹¹ÎÉÂÒ¡¢¼ÙСҶÐγÉ×îÖÕ½øÕ¹Îª¸ÎÓ²»¯¡£ ¡¡¡¡ÂýÐÔÒÒÐ͸ÎÑ×µÄ×é֯ѧÕï¶ÏÄÚÈݰüÀ¨Óв¡Ôѧ¡¢Ñ×Ö¢»µËÀ»î¶¯¶È¼°¸ÎÏËά»¯µÄ³Ì¶È¡£¸Î×éÖ¯Ñ×Ö¢»µËÀµÄ·Ö¼¶£¨G1~4£©¡¢ÏËά»¯³Ì¶ÈµÄ·ÖÆÚ£¨S1~4£©[45]¡£ ¡¡¡¡¾Å¡¢ÖÎÁƵÄ×ÜÌåÄ¿±ê ¡¡¡¡ÂýÐÔÒÒÐ͸ÎÑ×ÖÎÁƵÄ×ÜÌåÄ¿±êÊÇ£º×î´óÏ޶ȵس¤ÆÚÒÖÖÆHBV£¬¼õÇá¸Îϸ°ûÑ×Ö¢»µËÀ¼°¸ÎÏËά»¯£¬ÑÓ»ººÍ¼õÉÙ¸ÎÔàʧ´ú³¥¡¢¸ÎÓ²»¯¡¢HCC¼°Æä²¢·¢Ö¢µÄ·¢Éú£¬´Ó¶ø¸ÄÉÆÉú»îÖÊÁ¿ºÍÑÓ³¤´æ»îʱ¼ä¡£ ¡¡¡¡ÂýÐÔÒÒÐ͸ÎÑ×ÖÎÁÆÖ÷Òª°üÀ¨¿¹²¡¶¾¡¢ÃâÒßµ÷½Ú¡¢¿¹Ñ׺Ϳ¹Ñõ»¯¡¢¿¹ÏËά»¯ºÍ¶ÔÖ¢ÖÎÁÆ£¬ÆäÖп¹²¡¶¾ÖÎÁÆÊǹؼü£¬Ö»ÒªÓÐÊÊÓ¦Ö¤£¬ÇÒÌõ¼þÔÊÐí£¬¾ÍÓ¦½øÐй淶µÄ¿¹²¡¶¾ÖÎÁÆ¡£ ¡¡¡¡Ê®¡¢¿¹²¡¶¾ÖÎÁƵÄÒ»°ãÊÊÓ¦Ö¤[26, 29-31] ¡¡¡¡Ò»°ãÊÊÓ¦Ö¤°üÀ¨£º(1) HBeAg ÑôÐÔÕߣ¬HBV DNA ¡Ý105 ¿½±´/m l£¨Ï൱ÓÚ2000 IU/mL£©£»HBeAgÒõÐÔÕߣ¬HBV DNA ¡Ý104 ¿½±´/m l£¨Ï൱ÓÚ2000 IU/mL£©£»(2) ALT ¡Ý2¡ÁULN£»ÈçÓøÉÈÅËØÖÎÁÆ£¬ALTÓ¦¡Ü10¡ÁULN£¬ÑªÇå×ܵ¨ºìËØÓ¦<2¡ÁULN£»(3) ALT <2 ¡ÁULN£¬µ«¸Î×é֯ѧÏÔʾKnodell HAI ¡Ý4£¬»òÑ×Ö¢»µËÀ¡ÝG2£¬»òÏËά»¯¡ÝS2¡£ ¡¡¡¡¶Ô³ÖÐøHBV DNAÑôÐÔ¡¢´ï²»µ½ÉÏÊöÖÎÁƱê×¼¡¢µ«ÓÐÒÔÏÂÇéÐÎÖ®Ò»Õߣ¬ÒàÓ¦¿¼ÂǸøÓ迹²¡¶¾ÖÎÁÆ ¡¡¡¡£¨1£©¶ÔALT´óÓÚÕý³£ÉÏÏÞÇÒÄêÁä>40ËêÕߣ¬Ò²Ó¦¿¼ÂÇ¿¹²¡¶¾ÖÎÁÆ (III)¡£ ¡¡¡¡£¨2£©¶ÔALT³ÖÐøÕý³£µ«ÄêÁä½Ï´óÕߣ¨>40Ë꣩£¬Ó¦ÃÜÇÐËæ·Ã£¬×îºÃ½øÐиλî¼ì£»Èç¹û¸Î×é֯ѧÏÔʾKnodell HAI ¡Ý4£¬»òÑ×Ö¢»µËÀ¡ÝG2£¬»òÏËά»¯¡ÝS2£¬Ó¦»ý¼«¸øÓ迹²¡¶¾ÖÎÁÆ[59]£¨II£©¡£ ¡¡¡¡£¨3£©¶¯Ì¬¹Û²ì·¢ÏÖÓм²²¡½øÕ¹µÄÖ¤¾Ý£¨ÈçÆ¢ÔàÔö´ó£©Õߣ¬½¨ÒéÐиÎ×é֯ѧ¼ì²é£¬±ØÒªÊ±¸øÓ迹²¡¶¾ÖÎÁÆ£¨III£©¡£ ¡¡¡¡ÔÚ¿ªÊ¼ÖÎÁÆÇ°Ó¦ÅųýÓÉÒ©Îï¡¢¾Æ¾«»òÆäËûÒòËØËùÖµÄALTÉý¸ß£¬Ò²Ó¦ÅųýÓ¦ÓýµÃ¸Ò©ÎïºóALTÔÝʱÐÔÕý³£¡£ÔÚÒ»Ð©ÌØÊⲡÀýÈç¸ÎÓ²»¯»ò·þÓÃÁª±½½á¹¹ÑÜÉúÎïÀàÒ©ÎïÕߣ¬ÆäASTˮƽ¿É¸ßÓÚALT£¬´Ëʱ¿É½«ASTˮƽ×÷ΪÖ÷ÒªÖ¸±ê¡£ ¡¡¡¡Ê®Ò»¡¢¸ÉÈÅËØaÖÎÁÆ ¡¡¡¡ÎÒ¹úÒÑÅú×¼ÆÕͨ¸ÉÈÅËØa£¨2a£¬2bºÍ1b£©ºÍ¾ÛÒÒ¶þ´¼»¯¸ÉÈÅËØa£¨2aºÍ2b£©ÓÃÓÚÖÎÁÆÂýÐÔÒÒÐ͸ÎÑס£ ¡¡¡¡ÜöÝÍ·ÖÎö±íÃ÷£¬ÆÕͨ¸ÉÈÅËØÖÎÁÆÂýÐÔÒÒÐ͸ÎÑ×»¼Õߣ¬HBeAgѪÇåת»»ÂÊ¡¢HBsAgÇå³ýÂÊ¡¢¸ÎÓ²»¯·¢ÉúÂÊ¡¢HCC·¢ÉúÂʾùÓÅÓÚδ¾¸ÉÈÅËØÖÎÁÆÕß [49]¡£ÓйØHBeAgÒõÐÔ»¼ÕßµÄ4ÏîËæ»ú¶ÔÕÕÊÔÑé±íÃ÷£¬ÖÎÁƽáÊøÊ±Ó¦´ðÂÊΪ38%~90%£¬ µ«³Ö¾ÃÓ¦´ðÂʽöΪ10%~47% (ƽ¾ù24%) [30, 31](¢ñ)¡£ ÓÐÑо¿ÈÏΪ£¬ÆÕͨIFN-a ÁƳÌÖÁÉÙ1Äê²ÅÄÜ»ñµÃ½ÏºÃµÄÁÆÐ§[29, 33, 34]£¨¢ò£©¡£ ¡¡¡¡¹ú¼Ê¶àÖÐÐÄËæ»ú¶ÔÕÕÁÙ´²ÊÔÑéÏÔʾ£¬HBeAgÑôÐÔµÄÂýÐÔÒÒÐ͸ÎÑ×»¼Õߣ¬¾ÛÒÒ¶þ´¼»¯¸ÉÈÅËØa-2a£¨PegIFN-a2a£©ÖÎÁÆ(87%ΪÑÇÖÞÈË) 48ÖÜ£¬Í£Ò©Ëæ·Ã24ÖÜʱHBeAgѪÇåѧת»»ÂÊΪ32%[36, 37]£»Í£Ò©Ëæ·Ã48ÖÜʱHBeAgѪÇåѧת»»Âʿɴï43% [50]¡£¹úÍâÑо¿ÏÔʾ£¬¶ÔÓÚHBeAgÑôÐÔµÄÂýÐÔÒÒÐ͸ÎÑ×£¬Ó¦ÓþÛÒÒ¶þ´¼»¯¸ÉÈÅËØa-2b£¨PegIFN-a2b£©Ò²¿ÉÈ¡µÃÀàËÆµÄHBVDNAÒÖÖÆ¡¢HBeAgѪÇåѧת»»¡¢HBsAgÏûʧÂÊ[51-53] ¡£ ¡¡¡¡¶ÔHBeAgÒõÐÔÂýÐÔÒÒÐ͸ÎÑ×»¼Õß (60%ΪÑÇÖÞÈË) ÓÃPegIFN-a2aÖÎÁÆ48ÖÜ£¬Í£Ò©ºóËæ·Ã24ÖÜʱHBV DNA <2´104¿½±´/mL£¨Ï൱ÓÚ2000 IU/mL£©µÄ»¼ÕßΪ43%[38]£¬Í£Ò©ºóËæ·Ã48ÖÜʱΪ42%£»HBsAgÏûʧÂÊÔÚÍ£Ò©Ëæ·Ã24ÖÜʱΪ3£¥£¬Í£Ò©Ëæ·ÃÖÁ3ÄêʱÔö¼ÓÖÁ8£¥[54]¡£ ¡¡¡¡(Ò») ¸ÉÈÅËØ¿¹²¡¶¾ÁÆÐ§µÄÔ¤²âÒòËØ ¡¡¡¡ÓÐÏÂÁÐÒòËØÕß³£¿ÉÈ¡µÃ½ÏºÃµÄÁÆÐ§£º(1) ÖÎÁÆÇ°ALTˮƽ½Ï¸ß£»(2) HBV DNA< 2´108 ¿½±´£¯ml£»[< 4´107 IU/mL] (3) Å®ÐÔ£» (4) ²¡³Ì¶Ì£»(5) ·ÇĸӤ´«²¥£»(6) ¸Î×éÖ¯Ñ×Ö¢»µËÀ½ÏÖØ£¬ÏËά»¯³Ì¶ÈÇ᣻(7) ¶ÔÖÎÁƵÄÒÀ´ÓÐԺã» (8) ÎÞHCV¡¢HDV»òHIVºÏ²¢¸ÐȾ£»£¨9£©HBV»ùÒòAÐÍ£»£¨10£©ÖÎÁÆ12»ò24ÖÜʱ£¬ÑªÇåHBVDNA²»Äܼì³ö[50-52, 54]£¨II£©¡£ ÆäÖÐÖÎÁÆÇ°ALT¡¢HBV DNAˮƽºÍHBV»ùÒòÐÍ£¬ÊÇÔ¤²âÁÆÐ§µÄÖØÒªÒòËØ[55, 56] ¡£ ¡¡¡¡ÓÐÑо¿±íÃ÷£¬ÔÚPEG IFN-a2a ÖÎÁƹý³ÌÖУ¬¶¨Á¿¼ì²âHBsAgˮƽ»òHBeAgˮƽ¶ÔÖÎÁÆÓ¦´ðÓнϺÃÔ¤²â×÷ÓÃ[57-59]¡£ ¡¡¡¡(¶þ) ¸ÉÈÅËØÖÎÁƵļà²âºÍËæ·Ã ¡¡¡¡ÖÎÁÆÇ°Ó¦¼ì²é£º(1) Éú»¯Ñ§Ö¸±ê£¬°üÀ¨ALT¡¢AST¡¢µ¨ºìËØ¡¢°×µ°°×¼°Éö¹¦ÄÜ£»(2) Ѫ³£¹æ¡¢Äò³£¹æ¡¢ÑªÌǼ°¼××´ÏÙ¹¦ÄÜ£»(3) ²¡¶¾Ñ§±êÖ¾£¬°üÀ¨HBsAg¡¢HBeAg¡¢¿¹-HBeºÍHBV DNAµÄ»ùÏß״̬»òˮƽ£»(4) ¶ÔÓÚÖÐÄêÒÔÉÏ»¼Õߣ¬Ó¦×÷Ðĵçͼ¼ì²éºÍ²âѪѹ£»(5) Åųý×ÔÉíÃâÒßÐÔ¼²²¡£»(6) ÄòÈËÈÞëĤ´ÙÐÔÏÙ¼¤ËØ (HCG) ¼ì²âÒÔÅųýÈÑÉï¡£ ¡¡¡¡ÖÎÁƹý³ÌÖÐÓ¦¼ì²é£º(1) ¿ªÊ¼ÖÎÁƺóµÄµÚ1¸öÔ£¬Ó¦Ã¿1~2Öܼì²é1´ÎѪ³£¹æ£¬ÒÔºóÿÔ¼ì²é1´Î£¬Ö±ÖÁÖÎÁƽáÊø£»(2) Éú»¯Ñ§Ö¸±ê£¬°üÀ¨ALT¡¢ASTµÈ£¬ÖÎÁÆ¿ªÊ¼ºóÿÔÂ1´Î£¬Á¬Ðø3´Î£¬ÒÔºóËæ²¡Çé¸ÄÉÆ¿Éÿ3¸öÔÂ1´Î£»(3) ²¡¶¾Ñ§±êÖ¾£¬ÖÎÁÆ¿ªÊ¼ºóÿ3¸öÔ¼ì²â1´ÎHBsAg¡¢HBeAg¡¢¿¹-HBeºÍHBV DNA£»(4) ÆäËû£¬Ã¿3¸öÔ¼ì²â1´Î¼××´ÏÙ¹¦ÄÜ¡¢ÑªÌǺÍÄò³£¹æµÈÖ¸±ê£»ÈçÖÎÁÆÇ°¾ÍÒÑ´æÔÚ¼××´ÏÙ¹¦ÄÜÒì³£»òÒÑ»¼ÌÇÄò²¡Õߣ¬Ó¦ÏÈÓÃÒ©Îï¿ØÖÆ¼××´ÏÙ¹¦ÄÜÒì³£»òÌÇÄò²¡£¬È»ºóÔÙ¿ªÊ¼¸ÉÈÅËØÖÎÁÆ£¬Í¬Ê±Ó¦Ã¿Ô¼ì²é¼××´ÏÙ¹¦ÄܺÍѪÌÇˮƽ£»(5) Ó¦¶¨ÆÚÆÀ¹À¾«Éñ״̬£¬¶Ô³öÏÖÃ÷ÏÔÒÖÓôÖ¢ºÍÓÐ×ÔɱÇãÏòµÄ»¼Õߣ¬Ó¦Á¢¼´Í£Ò©²¢ÃÜÇм໤¡£ ¡¡¡¡ (Èý) ¸ÉÈÅËØµÄ²»Á¼·´Ó¦¼°Æä´¦Àí[51] ¡¡¡¡1£®Á÷¸ÐÑùÖ¢ºòȺ ±íÏÖΪ·¢ÈÈ¡¢º®Õ½¡¢Í·Í´¡¢¼¡ÈâËáÍ´ºÍ·¦Á¦µÈ£¬¿ÉÔÚ˯ǰעÉäIFN-a£¬»òÔÚ×¢Éä¸ÉÈÅËØÍ¬Ê±·þÓýâÈÈÕòÍ´Ò©¡£ ¡¡¡¡2£®Ò»¹ýÐÔÍâÖÜѪϸ°û¼õÉÙ Ö÷Òª±íÏÖΪÍâÖÜѪ°×ϸ°û (ÖÐÐÔÁ£Ï¸°û) ºÍѪС°å¼õÉÙ¡£ÈçÖÐÐÔÁ£Ï¸°û¾ø¶Ô¼ÆÊý ¡Ü0.75¡Á109/LºÍ£¨»ò£©ÑªÐ¡°å < 50¡Á109/L£¬Ó¦½µµÍIFN-¦Á¼ÁÁ¿£»1~2Öܺ󸴲飬Èç»Ö¸´£¬ÔòÖð½¥Ôö¼ÓÖÁÔÁ¿¡£ÈçÖÐÐÔÁ£Ï¸°û¾ø¶Ô¼ÆÊý ¡Ü0.5¡Á109/LºÍ£¨»ò£©ÑªÐ¡°å < 30¡Á109/L£¬ÔòӦͣҩ¡£¶ÔÖÐÐÔÁ£Ï¸°ûÃ÷ÏÔ½µµÍÕߣ¬¿ÉÊÔÓÃÁ£Ï¸°û¼¯Âä´Ì¼¤Òò×Ó (G-CSF) »òÁ£Ï¸°û¾ÞÊÉϸ°û¼¯Âä´Ì¼¤Òò×Ó (GM-CSF) ÖÎÁÆ (¢ó)¡£ ¡¡¡¡3£®¾«ÉñÒì³£ ¿É±íÏÖΪÒÖÓô¡¢ÍýÏë¡¢ÖØ¶È½¹ÂǵȾ«Éñ²¡Ö¢×´¡£¶ÔÖ¢×´ÑÏÖØÕߣ¬Ó¦¼°Ê±Í£ÓÃIFN-a£¬±ØÒªÊ±»áͬÉñ¾¾«Éñ¿ÆÒ½Ê¦½øÒ»²½ÕïÖΡ£ ¡¡¡¡4£®×ÔÉíÃâÒßÐÔ¼²²¡ һЩ»¼Õ߿ɳöÏÖ×ÔÉí¿¹Ì壬½öÉÙ²¿·Ö»¼Õß³öÏÖ¼××´ÏÙ¼²²¡ (¼××´ÏÙ¹¦ÄܼõÍË»ò¿º½ø)¡¢ÌÇÄò²¡¡¢ÑªÐ¡°å¼õÉÙ¡¢ÒøÐ¼²¡¡¢°×°ß¡¢Àà·çʪ¹Ø½ÚÑ׺ÍϵͳÐÔºì°ßÀÇ´¯Ñù×ÛºÏÕ÷µÈ£¬Ó¦ÇëÏà¹Ø¿ÆÊÒҽʦ»áÕﹲͬÕïÖΣ¬ÑÏÖØÕßӦͣҩ¡£ ¡¡¡¡5£®ÆäËûÉÙ¼ûµÄ²»Á¼·´Ó¦ °üÀ¨ÉöÔàË𺦠(¼äÖÊÐÔÉöÑס¢Éö²¡×ÛºÏÕ÷ºÍ¼±ÐÔÉöË¥½ßµÈ)¡¢ÐÄѪ¹Ü²¢·¢Ö¢ (ÐÄÂÉʧ³£¡¢È±ÑªÐÔÐÄÔಡºÍÐ¡µÈ)¡¢ÊÓÍøÄ¤²¡±ä¡¢ÌýÁ¦Ï½µºÍ¼äÖÊÐÔ·ÎÑ׵ȣ¬Ó¦Í£Ö¹¸ÉÈÅËØÖÎÁÆ¡£ ¡¡¡¡(ËÄ) ¸ÉÈÅËØÖÎÁƵĽû¼ÉÖ¤ ¡¡¡¡¸ÉÈÅËØÖÎÁƵľø¶Ô½û¼ÉÖ¤°üÀ¨£ºÈÑÉï¡¢¾«Éñ²¡Ê· (ÈçÑÏÖØÒÖÓôÖ¢)¡¢Î´ÄÜ¿ØÖƵÄñ²ðδ½ä¶ÏµÄÐï¾Æ/Îü¶¾Õß¡¢Î´¾¿ØÖƵÄ×ÔÉíÃâÒßÐÔ¼²²¡¡¢Ê§´ú³¥ÆÚ¸ÎÓ²»¯¡¢ÓÐÖ¢×´µÄÐÄÔಡ¡£ ¡¡¡¡¸ÉÈÅËØÖÎÁƵÄÏà¶Ô½û¼ÉÖ¤°üÀ¨£º¼××´ÏÙ¼²²¡¡¢ÊÓÍøÄ¤²¡¡¢ÒøÐ¼²¡¡¢¼ÈÍùÒÖÓô֢ʷ£¬Î´¿ØÖƵÄÌÇÄò²¡¡¢¸ßѪѹ£¬ÖÎÁÆÇ°ÖÐÐÔÁ£Ï¸°û¼ÆÊý <1.0 ´ 109/LºÍ£¨»ò£©ÑªÐ¡°å¼ÆÊý <50 ´ 109/L£¬×ܵ¨ºìËØ>51 mmol/L£¨ÌرðÊÇÒÔ¼ä½Óµ¨ºìËØÎªÖ÷Õß¡££© ¡¡¡¡Ê®¶þ¡¢ºËÜÕ£¨ËᣩÀàËÆÎïÖÎÁÆ ¡¡¡¡£¨Ò»£©Ä¿Ç°ÒÑÓ¦ÓÃÓÚÁÙ´²µÄ¿¹HBVºËÜÕ£¨ËᣩÀàËÆÎïÒ©ÎïÓÐ5ÖÖ£¬ÎÒ¹úÒÑÉÏÊÐ4ÖÖ¡£ ¡¡¡¡1. ÀÃ×·ò¶¨£¨lamivudine£¬ LAM£© ¡¡¡¡¹úÄÚÍâËæ»ú¶ÔÕÕÁÙ´²ÊÔÑé½á¹û±íÃ÷£¬Ã¿ÈÕ1´Î¿Ú·þ100 mgÀÃ×·ò¶¨¿ÉÃ÷ÏÔÒÖÖÆHBV DNAˮƽ; HBeAgѪÇåѧת»»ÂÊËæÖÎÁÆÊ±¼äÑÓ³¤¶øÌá¸ß£¬ÖÎÁÆ1¡¢2¡¢3¡¢4ºÍ5Äêʱ·Ö±ðΪ16%¡¢17%¡¢23%¡¢28£¥ºÍ35£¥[60]£»ÖÎÁÆÇ°ALTˮƽ½Ï¸ßÕߣ¬ÆäHBeAgѪÇåѧת»»Âʽϸß[61-64]¡£Ëæ»ú˫äÁÙ´²ÊÔÑé±íÃ÷£¬ÂýÐÔÒÒÐ͸ÎÑ×°éÃ÷ÏÔ¸ÎÏËά»¯ºÍ´ú³¥ÆÚ¸ÎÓ²»¯»¼Õß¾ÀÃ×·ò¶¨ÖÎÁÆ3Äê¿ÉÑÓ»º¼²²¡½øÕ¹¡¢½µµÍ¸Î¹¦ÄÜʧ´ú³¥¼°¸Î°©µÄ·¢ÉúÂÊ[65, 66]¡£Ê§´ú³¥ÆÚ¸ÎÓ²»¯»¼Õß¾ÀÃ×·ò¶¨ÖÎÁƺóÒ²ÄܸÄÉÆ¸Î¹¦ÄÜ£¬ÑÓ³¤Éú´æÆÚ[67-69]¡£¹úÍâÑо¿½á¹ûÏÔʾ£¬ÀÃ×·ò¶¨ÖÎÁƶùͯÂýÐÔÒÒÐ͸ÎÑ×µÄÁÆÐ§Óë³ÉÈËÏàËÆ£¬°²È«ÐÔÁ¼ºÃ[70, 71]¡£ÎÒ¹úÁÙ´²Ñо¿Ò²ÏÔʾÏàËÆµÄÁÙ´²ÁÆÐ§ºÍ°²È«ÐÔ[72]¡£ ¡¡¡¡ÀÃ×·ò¶¨²»Á¼·´Ó¦·¢ÉúÂʵͣ¬°²È«ÐÔÀàËÆ°²Î¿¼Á¡£ËæÖÎÁÆÊ±¼äÑÓ³¤£¬²¡¶¾ÄÍÒ©Í»±äµÄ·¢ÉúÂÊÔö¸ß (µÚ1¡¢2¡¢3¡¢4Äê·Ö±ðΪ14%¡¢38%¡¢49%ºÍ66%)[60, 72, 73]¡£ ¡¡¡¡2.°¢µÂ¸£Î¤õ¥ (adefovir dipivoxil, ADV) ¡¡¡¡¹úÄÚÍâËæ»ú˫äÁÙ´²ÊÔÑé±íÃ÷£¬HBeAgÑôÐÔÂýÐÔÒÒÐ͸ÎÑ×»¼Õ߿ڷþ°¢µÂ¸£Î¤õ¥¿ÉÃ÷ÏÔÒÖÖÆHBV DNA¸´ÖÆ[74, 75]¡¢ ´Ù½øALT¸´³£¡¢¸ÄÉÆ¸Î×éÖ¯Ñ×Ö¢»µËÀºÍÏËά»¯[76]¡£¶ÔHBeAgÑôÐÔ»¼ÕßÖÎÁÆ1¡¢2¡¢3Äêʱ£¬HBV DNA<1000 ¿½±´/mLÕß·Ö±ðΪ28%¡¢45%ºÍ56%£¬HBeAgѪÇåѧת»»ÂÊ·Ö±ðΪ12%¡¢29%ºÍ43%£»ÄÍÒ©ÂÊ·Ö±ðΪ0%¡¢1.6%ºÍ3.1%[76]¡£¶ÔHBeAgÒõÐÔ»¼ÕßÖÎÁÆ5Ä꣬HBV DNA<1000 ¿½±´/mLÕßΪ67%¡¢ALT¸´³£ÂÊΪ69%£»ÖÎÁÆ4Äê¡¢5Äêʱ£¬ÓиÎÔàÑ×Ö¢»µËÀºÍÏËά»¯³Ì¶È¸ÄÉÆÕß·Ö±ðΪ83%ºÍ73%£»ÖÎÁÆ5Äêʱ»¼ÕßµÄÀÛ»ýÄÍÒ©»ùÒòÍ»±ä·¢ÉúÂÊΪ29%¡¢²¡¶¾Ñ§ÄÍÒ©·¢ÉúÂÊΪ20%¡¢ÁÙ´²ÄÍÒ©·¢ÉúÂÊΪ11%£»Çá¶È¼¡ôûÉý¸ßÕßΪ3%[77-79]¡£ ¡¡¡¡°¢µÂ¸£Î¤õ¥ÁªºÏÀÃ×·ò¶¨£¬¶ÔÓÚÀÃ×·ò¶¨ÄÍÒ©µÄÂýÐÔÒÒÐ͸ÎÑ×ÄÜÓÐЧÒÖÖÆHBV DNA¡¢´Ù½øALT¸´³££¬ÇÒÁªºÏÓÃÒ©Õß¶Ô°¢µÂ¸£Î¤õ¥µÄÄÍÒ©·¢ÉúÂʸüµÍ[80-82]¡£¶àÏîÑо¿½á¹ûÏÔʾ£¬¶Ô·¢ÉúÀÃ×·ò¶¨ÄÍÒ©µÄ´ú³¥ÆÚºÍʧ´ú³¥ÆÚ¸ÎÓ²»¯»¼Õߣ¬ÁªºÏ°¢µÂ¸£Î¤õ¥ÖÎÁƾùÓÐЧ[83-86]¡£ ¡¡¡¡3.¶÷Ìæ¿¨Î¤ (entecavir, ETV) ¡¡¡¡Ò»ÏîËæ»ú˫ä¶ÔÕÕÁÙ´²ÊÔÑé±íÃ÷£¬¶ÔÓÚHBeAgÑôÐÔÂýÐÔÒҸλ¼Õߣ¬¶÷Ìæ¿¨Î¤ÖÎÁÆ48ÖÜʱHBV DNAϽµÖÁ300¿½±´/mLÒÔÏÂÕßΪ67%¡¢ALT¸´³£ÕßΪ68%¡¢ÓиÎ×é֯ѧ¸ÄÉÆÕßΪ72%£¬¾ùÓÅÓÚ½ÓÊÜÀÃ×·ò¶¨ÖÎÁÆÕߣ»µ«Á½×éHBeAgѪÇåת»»ÂÊÏàËÆ£¨21%ºÍ18%£©[87]¡£¶ÔÓÚHBeAgÒõÐÔ»¼Õߣ¬¶÷Ìæ¿¨Î¤ÖÎÁÆ48ÖÜʱHBV DNAϽµÖÁPCR¼ì²âˮƽÒÔÏÂÕßΪ90%¡¢ALT¸´³£ÂÊΪ78%¡¢¸Î×é֯ѧ¸ÄÉÆÂÊΪ70% [88]¡£ ¡¡¡¡³¤ÆÚËæ·ÃÑо¿±íÃ÷£¬¶Ô´ïµ½²¡¶¾Ñ§Ó¦´ðÕߣ¬¼ÌÐøÖÎÁƿɱ£³Ö½Ï¸ßµÄHBVDNAÒÖÖÆÐ§¹û[89]¡£ÈÕ±¾Ò»ÏîÑо¿ÏÔʾ¶÷Ìæ¿¨Î¤3ÄêÀÛ»ýÄÍÒ©ÂÊΪ1.7£¥~3.3£¥[90]¡£Ñо¿½á¹û»¹Ìáʾ£¬ÀÃ×·ò¶¨ÖÎÁÆÊ§°Ü»¼ÕßʹÓö÷Ìæ¿¨Î¤Ã¿ÈÕ1.0mgÒàÄÜÒÖÖÆHBV DNA¡¢¸ÄÉÆÉú»¯Ö¸±ê£¬µ«ÁÆÐ§½Ï³õÖÎÕß½µµÍ£¬ÇÒ²¡¶¾Ñ§Í»ÆÆ·¢ÉúÂÊÃ÷ÏÔÔö¸ß[91]£¬¹Ê²»ÒËÔÙÌᳫ¡£ÎÒ¹úµÄÁÙ´²ÊÔÑé½á¹ûÓëÒÔÉϱ¨µÀ»ù±¾ÏàËÆ[92, 93]¡£ ¡¡¡¡4.Ìæ±È·ò¶¨£¨telbivudine£¬LdT£© ¡¡¡¡Ò»ÏîΪÆÚ2ÄêµÄÈ«Çò¶àÖÐÐÄÁÙ´²ÊÔÑé±íÃ÷[94, 95]£¬ HBeAgÑôÐÔ»¼ÕßÖÎÁÆ52ÖÜʱ£¬Ìæ±È·ò¶¨×éHBV DNAϽµÖÁPCR·¨¼ì²âˮƽÒÔÏÂÕßΪ60.0%¡¢ALT¸´³£ÂÊΪ77.2%¡¢¡¢ÄÍÒ©·¢ÉúÂÊΪ5.0%¡¢¸Î×é֯ѧӦ´ðÂÊΪ64.7%£¬¾ùÓÅÓÚÀÃ×·ò¶¨ÖÎÁÆ×飬µ«Æä HBeAgѪÇåת»»ÂÊ£¨22.5%£©ÓëºóÕßÏàËÆ£»HBeAgÒõÐÔ»¼ÕßÖÎÁÆ52ÖÜʱ£¬ÆäHBV DNAÒÖÖÆ¡¢ALT¸´³£Âʼ°ÄÍÒ©·¢ÉúÂÊÒàÓÅÓÚÀÃ×·ò¶¨×é¡£ÖÎÁÆ2Äêʱ£¬Æä×ÜÌåÁÆÐ§£¨³ýHBeAgÏûʧ¼°ÑªÇåת»»ÂÊÍ⣩ºÍÄÍÒ©·¢ÉúÂÊÒàÓÅÓÚÀÃ×·ò¶¨×é[94]¡£ ÎÒ¹úµÄ¶àÖÐÐÄÁÙ´²ÊÔÑéÒ²±íÃ÷Æä¿¹²¡¶¾»îÐÔºÍÄÍÒ©·¢ÉúÂʾùÓÅÓÚÀÃ×·ò¶¨[96]¡£¹úÄÚÍâÁÙ´²Ñо¿Ìáʾ£¬»ùÏßHBV DNA<109¿½±´/mL ¼°ALT³2ULNµÄHBeAgÑôÐÔ»¼Õߣ¬»òHBV DNA<107¿½±´/mL µÄHBeAgÒõÐÔ»¼Õߣ¬¾Ìæ±È·ò¶¨ÖÎÁÆ24ÖÜʱÈç´ïµ½HBVDNA©‚300¿½±´/mL£¬ÖÎÁƵ½1Äê¡¢2ÄêʱÓиüºÃµÄÁÆÐ§ºÍ½ÏµÍµÄÄÍÒ©·¢ÉúÂÊ[97, 98]¡£ ¡¡¡¡Ìæ±È·ò¶¨µÄ×ÜÌå²»Á¼Ê¼þ·¢ÉúÂʺÍÀÃ×·ò¶¨ÏàËÆ£¬µ«ÖÎÁÆ52ÖܺÍ104ÖÜʱ·¢Éú3-4¼¶¼¡Ëἤø£¨CK£©Éý¸ßÕßΪ·Ö±ð7.5% ºÍ12.9%£¬¶øÀÃ×·ò¶¨×é·Ö±ðΪ3.1%ºÍ4.1%[94, 95]¡£ ¡¡¡¡ 5. ÌæÅµ¸£Î¤õ¥£¨tenofovir disoproxil fumarate£¬TDF£© ¡¡¡¡TDFÓë°¢µÂ¸£Î¤õ¥½á¹¹ÏàËÆ£¬µ«Éö¶¾ÐÔ½ÏС£¬ÖÎÁƼÁÁ¿ÎªÃ¿ÈÕ300mg¡£±¾Ò©ÔÚÎÒ¹úÉÐδ±»Åú×¼ÉÏÊС£ ¡¡¡¡ÔÚÒ»ÏîËæ»ú˫ä¶ÔÕÕÁÙ´²ÊÔÑéÖУ¬TDF»òADVÖÎÁÆHBeAgÑôÐÔ»¼Õß HBVDNA£¼400 ¿½±´/mLÕß·Ö±ðΪ76£¥ºÍ13£¥£¬ALT¸´³£ÂÊ·Ö±ðΪ68%ºÍ54%£»¶ÔHBeAgÒõÐÔÂýÐÔÒÒÐ͸ÎÑ×48ÖÜʱHBVDNA£¼400 ¿½±´/mLÕß·Ö±ðΪ93%ºÍ63%£»¸ÃÑо¿ÏÔʾÒÖÖÆHBVµÄ×÷ÓÃÓÅÓÚADV£¬Î´·¢ÏÖÓëÌæÅµ¸£Î¤õ¥ÓйصÄÄÍÒ©Í»±ä[99]¡£³ÖÐøÓ¦ÓÃÌæÅµ¸£Î¤õ¥ÖÎÁÆ3Äêʱ£¬72%µÄHBeAgÑôÐÔ»¼ÕߺÍ87% HBeAgÒõÐÔ»¼ÕßѪÇåHBVDNA£¼400 ¿½±´/mL£¬Òàδ·¢ÏÖÄÍÒ©±äÒì[100]¡£ ¡¡¡¡£¨¶þ£©ºËÜÕ£¨ËᣩÀàËÆÎïÖÎÁƵÄÏà¹ØÎÊÌâ ¡¡¡¡1.ÖÎÁÆÇ°Ïà¹ØÖ¸±ê»ùÏß¼ì²â: £¨2£©Éú»¯Ñ§Ö¸±ê£¬Ö÷ÒªÓÐALT¡¢AST¡¢µ¨ºìËØ¡¢°×µ°°×µÈ£»£¨2£©²¡¶¾Ñ§±êÖ¾£¬Ö÷ÒªÓÐHBV DNAºÍHBeAg¡¢¿¹-HBe£»£¨3£©¸ù¾Ý²¡ÇéÐèÒª£¬¼ì²âѪ³£¹æ¡¢ÑªÇ弡ôûºÍ¼¡ËἤøµÈ¡£ÈçÌõ¼þÔÊÐí£¬ÖÎÁÆÇ°ºó×îºÃÐиδ©´Ì¼ì²é¡£ ¡¡¡¡2.ÖÎÁƹý³ÌÖÐÏà¹ØÖ¸±ê¶¨ÆÚ¼à²â: £¨1£©Éú»¯Ñ§Ö¸±ê£¬ÖÎÁÆ¿ªÊ¼ºóÿÔÂ1´Î¡¢Á¬Ðø3´Î£¬ÒÔºóËæ²¡Çé¸ÄÉÆ¿Éÿ3¸öÔÂ1´Î£»£¨2£©²¡¶¾Ñ§±êÖ¾£¬Ö÷Òª°üÀ¨HBV DNAºÍHBeAg¡¢¿¹-HBe£¬Ò»°ãÖÎÁÆ¿ªÊ¼ºó1-3¸öÔ¼ì²â1´Î£¬ÒÔºóÿ3-6¸öÔ¼ì²â1´Î£»£¨3£©¸ù¾Ý²¡ÇéÐèÒª£¬¶¨ÆÚ¼ì²âѪ³£¹æ¡¢ÑªÇ弡ôûºÍ¼¡ËἤøµÈÖ¸±ê¡£ ¡¡¡¡3.Ô¤²âÁÆÐ§ºÍÓÅ»¯ÖÎÁÆ: ÓÐÑо¿±íÃ÷£¬³ý»ùÏßÒòËØÍ⣬ÖÎÁÆÔçÆÚ²¡¶¾Ñ§Ó¦´ðÇé¿ö¿ÉÔ¤²âÆä³¤ÆÚÁÆÐ§ºÍÄÍÒ©·¢ÉúÂÊ[98, 101]¡£¹úÍâ¾Ý´ËÌá³öÁ˺ËÜÕ£¨ËᣩÀàËÆÎïÖÎÁÆÂýÐÔÒÒÐ͸ÎÑ׵ķÏßͼ¸ÅÄî[102]£¬Ç¿µ÷ÖÎÁÆÔçÆÚ²¡¶¾Ñ§Ó¦´ðµÄÖØÒªÐÔ£¬²¢Ìᳫ¸ù¾ÝHBV DNA¼à²â½á¹û¸øÓèÓÅ»¯ÖÎÁÆ¡£µ«ÊÇ£¬¸÷¸öÒ©ÎïµÄ×î¼Ñ¼à²âʱ¼äµãºÍÅжϽçÖµ¿ÉÄÜÓÐËù²»Í¬¡£¶øÇÒ£¬¶ÔÓÚÓ¦´ð²»³ä·ÖÕߣ¬²ÉÓúÎÖÖÖÎÁƲßÂԺͷ½·¨¸üÓÐЧ£¬ÉÐÐèǰհÐÔÁÙ´²Ñо¿À´ÑéÖ¤¡£ ¡¡¡¡4. ÃÜÇйØ×¢»¼ÕßÖÎÁÆÒÀ´ÓÐÔÎÊÌâ: °üÀ¨ÓÃÒ©¼ÁÁ¿¡¢Ê¹Ó÷½·¨¡¢ÊÇ·ñÓЩÓÃÒ©Îï»ò×ÔÐÐÍ£Ò©µÈÇé¿ö£¬È·±£»¼ÕßÒѾÁ˽âËæÒâÍ£Ò©¿ÉÄܵ¼ÖµķçÏÕ£¬Ìá¸ß»¼ÕßÒÀ´ÓÐÔ¡£ ¡¡¡¡5.ÉÙ¼û¡¢º±¼û²»Á¼·´Ó¦µÄÔ¤·ÀºÍ´¦Àí£ººËÜÕ£¨ËᣩÀàËÆÎï×ÜÌ尲ȫÐÔºÍÄÍÊÜÐÔÁ¼ºÃ£¬µ«ÔÚÁÙ´²Ó¦ÓÃÖÐÈ·ÓÐÉÙ¼û¡¢º±¼ûÑÏÖØ²»Á¼·´Ó¦µÄ·¢Éú£¬ÈçÉö¹¦Äܲ»È«¡¢¼¡Ñס¢ºáÎÆ¼¡Èܽ⡢ÈéËáËáÖж¾µÈ£¬Ó¦ÒýÆð¹Ø×¢¡£½¨ÒéÖÎÁÆÇ°×ÐϸѯÎÊÏà¹Ø²¡Ê·£¬ÒÔ¼õÉÙ·çÏÕ¡£¶ÔÖÎÁÆÖгöÏÖѪ¼¡ôû¡¢CK»òÈéËáÍÑÇâøÃ÷ÏÔÉý¸ß£¬²¢°éÏàÓ¦ÁÙ´²±íÏÖÕßÈçÈ«ÉíÇé¿ö±ä²î¡¢Ã÷ÏÔ¼¡Í´¡¢¼¡ÎÞÁ¦µÈÖ¢µÄ»¼Õߣ¬Ó¦ÃÜÇй۲죬һµ©È·ÕïΪÄò¶¾Ö¢¡¢¼¡Ñס¢ºáÎÆ¼¡Èܽâ»òÈéËáËáÖж¾µÈ£¬Ó¦¼°Ê±Í£Ò©»ò¸ÄÓÃÆäËüÒ©Î²¢¸øÓè»ý¼«µÄÏàÓ¦ÖÎÁƸÉÔ¤¡£ ¡¡¡¡Ê®Èý¡¢ÃâÒßµ÷½ÚÖÎÁÆ ¡¡¡¡ÃâÒßµ÷½ÚÖÎÁÆÓÐÍû³ÉΪÖÎÁÆÂýÐÔÒÒÐ͸ÎÑ×µÄÖØÒªÊֶΣ¬µ«Ä¿Ç°ÉÐȱ·¦ÁÆÐ§È·ÇеÄÒÒÐ͸ÎÑ×ÌØÒìÐÔÃâÒßÁÆ·¨¡£ÐØÏÙëĦÁ1¿ÉÔöÇ¿»úÌå·ÇÌØÒìÐÔÃâÒß¹¦ÄÜ¡¢²»Á¼·´Ó¦Ð¡¡¢ÄÍÊÜÐÔÁ¼ºÃ£¬¶ÔÓÚÓп¹²¡¶¾ÊÊÓ¦Ö¤£¬µ«²»ÄÜÄÍÊÜ»ò²»Ô¸½ÓÊܸÉÈÅËØ»òºËÜÕ (Ëá) ÀàËÆÎïÖÎÁƵϼÕߣ¬ÈçÓÐÌõ¼þ¿ÉÓÃÐØÏÙëĦÁ1 1.6mg£¬Ã¿ÖÜ2´Î£¬Æ¤ÏÂ×¢É䣬ÁƳÌ6¸öÔ (II-3)[103, 104]¡£ÐØÏÙëĦÁ1ÁªºÏÆäËû¿¹ÒÒÐ͸ÎÑײ¡¶¾Ò©ÎïµÄÁÆÐ§ÉÐÐè´óÑù±¾Ëæ»ú¶ÔÕÕÁÙ´²Ñо¿ÑéÖ¤¡£ ¡¡¡¡Ê®ËÄ¡¢ÖÐÒ©¼°ÖÐÒ©ÖÆ¼ÁÖÎÁÆ ¡¡¡¡ÖÐÒ½Ò©ÖÆ¼ÁÖÎÁÆÂýÐÔÒÒÐ͸ÎÑ×ÔÚÎÒ¹úÓ¦Óù㷺£¬¶ÔÓÚ¸ÄÉÆÁÙ´²Ö¢×´ºÍ¸Î¹¦ÄÜÖ¸±êÓÐÒ»¶¨Ð§¹û£¬µ«ÉÐÐèÉè¼ÆÑϽ÷¡¢Ö´ÐÐÑϸñµÄ´óÑù±¾Ëæ»ú¶ÔÕÕÁÙ´²Ñо¿À´ÑéÖ¤Æä¿¹²¡¶¾Ð§¹û¡£ ¡¡¡¡Ê®Îå¡¢¿¹²¡¶¾ÖÎÁÆÍƼöÒâ¼û ¡¡¡¡(Ò») ÂýÐÔHBVЯ´øÕߺͷǻÐÔHBsAgЯ´øÕß ¡¡¡¡ÂýÐÔHBVЯ´øÕßÔÝʱ²»Ð迹²¡¶¾ÖÎÁÆ¡£µ«Ó¦Ã¿3~6¸öÔ½øÐÐÉú»¯Ñ§¡¢²¡¶¾Ñ§¡¢¼×Ì¥µ°°×ºÍÓ°Ïñѧ¼ì²é£¬Èô·ûºÏ¿¹²¡¶¾ÖÎÁÆÊÊÓ¦Ö¤£¬¿ÉÓÃIFN-a »òºËÜÕ (Ëá) ÀàËÆÎïÖÎÁÆ (¢ò-2)¡£ ¶ÔÄêÁä>40Ëê£¬ÌØ±ðÊÇÄÐÐÔ»òÓÐHCC¼Ò×åÊ·Õߣ¬¼´Ê¹ALTÕý³£»òÇá¶ÈÉý¸ß£¬Ò²Ç¿ÁÒ½¨Òé×ö¸Î×é֯ѧ¼ì²éÈ·¶¨ÆäÊÇ·ñ¿¹²¡¶¾ÖÎÁÆ¡£ ¡¡¡¡·Ç»î¶¯ÐÔHBsAgЯ´øÕßÒ»°ã²»Ð迹²¡¶¾ÖÎÁÆ£¬µ«Ó¦Ã¿6¸öÔ½øÐÐÒ»´ÎÉú»¯¡¢HBVDNA¡¢AFP¼°¸ÎÔ೬ÉùÏÔÏñ¼ì²é¡£ ¡¡¡¡ (¶þ) HBeAgÑôÐÔÂýÐÔÒÒÐ͸ÎÑ×»¼Õß ¡¡¡¡1£®ÆÕͨIFN-a 3~5 MU£¬Ã¿ÖÜ3´Î»ò¸ôÈÕ1´Î£¬Æ¤ÏÂ×¢É䣬һ°ãÁƳÌΪ6¸öÔ (I)¡£ÈçÓÐÓ¦´ð£¬ÎªÌá¸ßÁÆÐ§Òà¿ÉÑÓ³¤ÁƳÌÖÁ1Äê»ò¸ü³¤[51][(II)¡£¿É¸ù¾Ý»¼ÕßµÄÓ¦´ðºÍÄÍÊÜÇé¿öÊʵ±µ÷Õû¼ÁÁ¿¼°ÁƳ̣»ÈçÖÎÁÆ6¸öÔÂÈÔÎÞÓ¦´ð£¬¿É¸ÄÓûòÁªºÏÆäËû¿¹²¡¶¾Ò©Îï¡£ ¡¡¡¡2£®¾ÛÒÒ¶þ´¼IFN-a 2a 180 mg£¬Ã¿ÖÜ1´Î£¬Æ¤ÏÂ×¢É䣬ÁƳÌ1Äê (I)¡£¾ßÌå¼ÁÁ¿ºÍÁƳ̿ɸù¾Ý»¼ÕßµÄÓ¦´ð¼°ÄÍÊÜÐÔµÈÒòËØ½øÐе÷Õû¡£ ¡¡¡¡3£®¾ÛÒÒ¶þ´¼IFN-a 2b 1.0~1.5¦Ìg/kg£¬Ã¿ÖÜ1´Î£¬Æ¤ÏÂ×¢É䣬ÁƳÌ1Ä꣨I£©¡£¾ßÌå¼ÁÁ¿ºÍÁƳ̿ɸù¾Ý»¼ÕßµÄÓ¦´ð¼°ÄÍÊÜÐÔµÈÒòËØ½øÐе÷Õû¡£ ¡¡¡¡4£® ÀÃ×·ò¶¨ 100 mg£¬Ã¿ÈÕ1´Î¿Ú·þ¡£ÔÚ´ïµ½HBV DNAµÍÓÚ¼ì²âÏÂÏÞ¡¢ALT¸´³£¡¢HBeAg ѪÇåѧת»»ºó£¬ÔÙ¹®¹ÌÖÁÉÙ1Ä꣨¾¹ýÖÁÉÙÁ½´Î¸´²é£¬Ã¿´Î¼ä¸ô6¸öÔ£©ÈÔ±£³Ö²»±ä¡¢ÇÒ×ÜÁƳÌÖÁÉÙÒÑ´ï2ÄêÕߣ¬¿É¿¼ÂÇÍ£Ò©[84](II)£¬µ«ÑÓ³¤ÁƳ̿ɼõÉÙ¸´·¢¡£ ¡¡¡¡5£®°¢µÂ¸£Î¤õ¥ 10 mg£¬Ã¿ÈÕ1´Î¿Ú·þ¡£ÁƳ̿ɲÎÕÕÀÃ×·ò¶¨[84] (II)¡£ ¡¡¡¡6£®¶÷Ìæ¿¨Î¤ 0.5 mg£¬Ã¿ÈÕ1´Î¿Ú·þ¡£ÁƳ̿ɲÎÕÕÀÃ×·ò¶¨¡£ ¡¡¡¡7. Ìæ±È·ò¶¨ 600 mg£¬Ã¿ÈÕ1´Î¿Ú·þ¡£ÁƳ̿ɲÎÕÕÀÃ×·ò¶¨¡£ ¡¡¡¡(Èý) HBeAgÒõÐÔÂýÐÔÒÒÐ͸ÎÑ×»¼Õß ¡¡¡¡´ËÀ໼Õ߸´·¢Âʸߣ¬ÁƳÌÒ˳¤ (I)¡£×îºÃÑ¡ÓøÉÈÅËØÀà»òÄÍÒ©·¢ÉúÂʵ͵ĺËÜÕ (Ëá) ÀàËÆÎïÖÎÁÆ¡£ ¡¡¡¡1£®ÆÕͨIFN-a ¼ÁÁ¿Ó÷¨Í¬Ç°£¬ÁƳÌÖÁÉÙ1Äê (I)¡£ ¡¡¡¡2£®¾ÛÒÒ¶þ´¼IFN-a2a 180mg£¬¼ÁÁ¿Ó÷¨Í¬Ç°£¬ÁƳÌÖÁÉÙ1Äê (I)¡£¾ßÌå¼ÁÁ¿ºÍÁƳ̿ɸù¾Ý»¼ÕßÄÍÊÜÐÔµÈÒòËØ½øÐе÷Õû¡£ ¡¡¡¡3£®ÀÃ×·ò¶¨¡¢°¢µÂ¸£Î¤õ¥¡¢¶÷Ìæ¿¨Î¤ºÍÌæ±È·ò¶¨ ¼ÁÁ¿Ó÷¨Í¬Ç°£¬µ«ÁƳÌÓ¦¸ü³¤£ºÔÚ´ïµ½HBV DNAµÍÓÚ¼ì²âÏÂÏÞ¡¢ALTÕý³£ºó£¬ÖÁÉÙÔÚ¹®¹Ì1Äê°ë£¨¾¹ýÖÁÉÙ3´Î¸´²é£¬Ã¿´Î¼ä¸ô6¸öÔÂ)ÈÔ±£³Ö²»±ä¡¢ÇÒ×ÜÁƳÌÖÁÉÙÒÑ´ïµ½2Äê°ëÕߣ¬¿É¿¼ÂÇÍ£Ò©[76]£¨II£©¡£ÓÉÓÚÍ£Ò©ºó¸´·¢Âʽϸߣ¬¿ÉÒÔÑÓ³¤ÁƳ̡£ ¡¡¡¡(ËÄ) ´ú³¥ÆÚÒÒÐ͸ÎÑ׸ÎÓ²»¯»¼Õß ¡¡¡¡HBeAgÑôÐÔÕßµÄÖÎÁÆÖ¸Õ÷ΪHBV DNA ¡Ý104¿½±´/mL£¬HBeAgÒõÐÔÕßΪHBV DNA ¡Ý103¿½±´/mL£¬ALTÕý³£»òÉý¸ß¡£ÖÎÁÆÄ¿±êÊÇÑÓ»º»ò½µÉٸι¦ÄÜʧ´ú³¥ºÍHCCµÄ·¢Éú¡£ÒòÐèÒª½Ï³¤ÆÚÖÎÁÆ£¬×îºÃÑ¡ÓÃÄÍÒ©·¢ÉúÂʵ͵ĺËÜÕ (Ëá) ÀàËÆÎïÖÎÁÆ£¬ÆäÍ£Ò©±ê×¼Éв»Ã÷È·¡£ ¡¡¡¡¸ÉÈÅËØÒòÆäÓе¼Ö¸ι¦ÄÜʧ´ú³¥µÈ²¢·¢Ö¢µÄ¿ÉÄÜ£¬Ó¦Ê®·ÖÉ÷ÖØ¡£ÈçÈÏΪÓбØÒª£¬ÒË´ÓС¼ÁÁ¿¿ªÊ¼£¬¸ù¾Ý»¼ÕßµÄÄÍÊÜÇé¿öÖð½¥Ôö¼Óµ½Ô¤¶¨µÄÖÎÁƼÁÁ¿ (III)¡£ ¡¡¡¡(Îå) ʧ´ú³¥ÆÚÒÒÐ͸ÎÑ׸ÎÓ²»¯»¼Õß ¡¡¡¡¶ÔÓÚʧ´ú³¥ÆÚ¸ÎÓ²»¯»¼Õߣ¬Ö»ÒªÄܼì³öHBV DNA£¬²»ÂÛALT»òASTÊÇ·ñÉý¸ß£¬½¨ÒéÔÚÖªÇéͬÒâµÄ»ù´¡ÉÏ£¬¼°Ê±Ó¦ÓúËÜÕ£¨ËᣩÀàËÆÎ²¡¶¾ÖÎÁÆ£¬ÒÔ¸ÄÉÆ¸Î¹¦Äܲ¢ÑÓ»º»ò¼õÉÙ¸ÎÒÆÖ²µÄÐèÇó¡£ÒòÐèÒª³¤ÆÚÖÎÁÆ£¬Ó¦ºÃÑ¡ÓÃÄÍÒ©·¢ÉúÂʵ͵ĺËÜÕ (Ëá) ÀàËÆÎïÖÎÁÆ£¬²»ÄÜËæÒâÍ£Ò©£¬Ò»µ©·¢ÉúÄÍÒ©±äÒ죬Ӧ¼°Ê±¼ÓÓÃÆäËûÒÑÅú×¼µÄÄÜÖÎÁÆÄÍÒ©±äÒìµÄºËÜÕ (Ëá) ÀàËÆÎï (II£2)¡£ ¡¡¡¡¸ÉÈÅËØÖÎÁƿɵ¼Ö¸ÎË¥½ß£¬Òò´Ë£¬¶Ôʧ´ú³¥ÆÚ¸ÎÓ²»¯»¼ÕßÊô½û¼ÉÖ¤ (¢ò)¡£ ¡¡¡¡£¨Áù£©ºËÜÕ£¨ËᣩÀàËÆÎïÄÍÒ©µÄÔ¤·ÀºÍÖÎÁÆ ¡¡¡¡1.ÑϸñÕÆÎÕÖÎÁÆÊÊÓ¦Ö¤£º¶ÔÓÚ¸ÎÔàÑ×Ö¢²¡±äÇá΢¡¢ÄÑÒÔÈ¡µÃ³ÖÐøÓ¦´ðµÄ»¼Õߣ¨ÈçALTÕý³£¡¢HBeAgÑôÐÔµÄÃâÒßÄÍÊÜÆÚ£©£¬ÌرðÊǵ±ÕâЩ»¼Õߣ¼30Ëêʱ£¬Ó¦µ±¾¡Á¿±ÜÃâʹÓúËÜÕ£¨ËᣩÀàËÆÎïÖÎÁÆ¡£ ¡¡¡¡2.½÷É÷Ñ¡ÔñºËÜÕ£¨ËᣩÀàÒ©ÎÈçÌõ¼þÔÊÐí£¬¿ªÊ¼ÖÎÁÆÊ±ÒËÑ¡Óÿ¹²¡¶¾×÷ÓÃÇ¿ºÍÄÍÒ©·¢ÉúÂʵ͵ÄÒ©Îï¡£ ¡¡¡¡3. ÖÎÁÆÖÐÃÜÇмà²â¡¢¼°Ê±ÁªºÏÖÎÁÆ£º¶¨ÆÚ¼ì²âHBV DNA£¬ÒÔ¼°Ê±·¢ÏÖÔ·¢ÐÔÎÞÓ¦´ð»ò²¡¶¾Ñ§Í»ÆÆ¡£¶ÔºÏ²¢HIV ¸ÐȾ¡¢¸ÎÓ²»¯¼°¸ß²¡¶¾ÔØÁ¿µÈÔçÆÚÓ¦´ð²»¼ÑÕߣ¬Ò˾¡Ôç²ÉÓÃÎÞ½»²æÄÍҩλµãµÄºËÜÕ£¨ËᣩÀàÒ©ÎïÁªºÏÖÎÁÆ¡£ ¡¡¡¡4.Ò»µ©·¢ÏÖÄÍÒ©£¬¾¡Ôç¸øÓè¾ÈÔ®ÖÎÁÆ£º¶ÔÓÚ½ÓÊÜÀÃ×·ò¶¨ÖÎÁƵϼÕߣ¬Ò»µ©¼ì³ö»ùÒòÐÍÄÍÒ©»òHBV DNA¿ªÊ¼Éý¸ßʱ¾Í¼ÓÓð¢µÂ¸£Î¤õ¥ÁªºÏÖÎÁÆ£¬ÒÖÖÆ²¡¶¾¸ü¿ì¡¢ÄÍÒ©·¢Éú½ÏÉÙ¡¢ÁÙ´²½á¾Ö½ÏºÃ[95]¡£¹ØÓÚÆäËûÒ©ÎïÄÍÒ©»¼ÕßµÄÖÎÁÆÁÙ´²Ñо¿Ïà¶Ô½ÏÉÙ£¬ÓйصÄÖÎÁÆÍƼöÒâ¼ûÖ÷Òª¸ù¾ÝÌåÍâÑо¿½á¹û[120]¡£¶ÔÓÚÌæ±È·ò¶¨¡¢¶÷Ìæ¿¨Î¤·¢ÉúÄÍÒ©Õߣ¬Òà¿É¼ÓÓð¢µÂ¸£Î¤õ¥ÁªºÏÖÎÁÆ¡£¶ÔÓÚ°¢µÂ¸£Î¤õ¥ÄÍÒ©Õߣ¬¿É¼ÓÀÃ×·ò¶¨¡¢Ìæ±È·ò¶¨ÁªºÏÖÎÁÆ£»¶ÔÓÚδӦÓùýÆäËüºËÜÕÀàËÆÎïÕߣ¬Òà¿É»»Óö÷Ìæ¿¨Î¤¡£¶ÔÓÚºËÜÕ£¨ËᣩÀà·¢ÉúÄÍÒ©Õߣ¬Òà¿É¿¼ÂǸÄÓûò¼ÓÓøÉÈÅËØÀàÁªºÏÖÎÁÆ£¬µ«Ó¦±ÜÃâÌæ±È·ò¶¨ºÍPEG-IFN ÁªºÏÓ¦Óã¬ÒòΪ¿Éµ¼ÖÂÍâÖÜÉñ¾¼¡Èâ¼²²¡¡£ ¡¡¡¡5. ¾¡Á¿±ÜÃâµ¥Ò©Ðò¹áÖÎÁÆ£ºÓÐÁÙ´²Ñо¿ÏÔʾ£¬Òò¶ÔijһºËÜÕ£¨ËᣩÀà·¢ÉúÄÍÒ©¶øÏȺó¸ÄÓÃÆäËüÜÕ£¨ËᣩÀàÒ©ÎïÖÎÁÆ£¬¿Éɸѡ³ö¶Ô¶àÖÖÜÕ£¨ËᣩÀàÄÍÒ©µÄ±äÒìÖê¡£Òò´Ë£¬Ó¦±ÜÃâµ¥Ò©Ðò¹áÖÎÁÆ¡£ ¡¡¡¡Ê®Áù¡¢ÌØÊâÇé¿öµÄ´¦Àí ¡¡¡¡(Ò») ¾¹ý¹æ·¶µÄÆÕͨ¸ÉÈÅËØ¦Á»ò¾ÛÒÒ¶þ´¼»¯¸ÉÈÅËØ¦ÁÖÎÁÆÎÞÓ¦´ðµÄÂýÐÔÒÒÐ͸ÎÑ×»¼Õߣ¬ÈôÓÐÖÎÁÆÖ¸Õ÷¿ÉÒÔÑ¡ÓúËÜÕ£¨ËᣩÀàËÆÎïÔÙÖÎÁÆ£¨¢ñ£©¡£ ¡¡¡¡£¨¶þ£©¶ÔÓÚºËÜÕ£¨ËᣩÀàËÆÎï¹æ·¶ÖÎÁƺóÔ·¢ÐÔÎÞÓ¦´ðµÄ»¼Õߣ¬¼´ÖÎÁÆÖÁÉÙ6¸öÔÂʱѪÇåHBV DNAϽµ·ù¶È£¼2 log10£¬Ó¦¸Ä±äÖÎÁÆ·½°¸¼ÌÐøÖÎÁÆ£¨¢ó£©¡£ ¡¡¡¡ (Èý) Ó¦Óû¯ÁƺÍÃâÒßÒÖÖÆ¼ÁÖÎÁƵϼÕß ¡¡¡¡¶ÔÓÚÒòÆäËû¼²²¡¶ø½ÓÊÜ»¯ÁÆ¡¢ÃâÒßÒÖÖÆ¼ÁÖÎÁƵϼÕߣ¬Ó¦³£¹æÉ¸²éHBsAg£»ÈôΪÑôÐÔ£¬¼´Ê¹HBV DNAÒõÐÔºÍALTÕý³££¬Ò²Ó¦ÔÚÖÎÁÆÇ°1ÖÜ¿ªÊ¼·þÓÃÀÃ×·ò¶¨»òÆäËûºËÜÕ(Ëá)ÀàËÆÎï¡£ ¡¡¡¡¶ÔHBsAgÒõÐÔ¡¢¿¹HBcÑôÐÔ»¼Õߣ¬ÔÚ¸øÓ賤ÆÚ»ò´ó¼ÁÁ¿ÃâÒßÒÖÖÆ¼Á»òϸ°û¶¾Ò©Îï£¨ÌØ±ðÊÇÕë¶ÔB»òTÁܰÍϸ°ûµ¥¿Ë¡¿¹Ì壩ÖÎÁÆÊ±£¬Ó¦ÃÜÇмà²âHBV DNAºÍHBsAg£¬Èô³öÏÖÑôתÔòÓ¦¼°Ê±¼ÓÓÿ¹²¡¶¾ÖÎÁÆ[105]¡£ ¡¡¡¡ÔÚ»¯ÁƺÍÃâÒßÒÖÖÆ¼ÁÖÎÁÆÍ£Ö¹ºó£¬Ó¦¸ù¾Ý»¼Õß²¡Çé¾ö¶¨Í£Ò©Ê±¼ä (II-1, II-3)£º£¨1£©¶ÔÓÚ»ùÏßHBV DNA£¼2 000 IU/mLµÄ»¼Õߣ¬ÔÚÍê³É»¯ÁÆ»òÃâÒßÒÖÖÆ¼ÁÖÎÁƺó£¬Ó¦µ±¼ÌÐøÖÎÁÆ6¸öÔ£¨¢ó£©£»£¨2£©»ùÏßHBV DNAˮƽ½Ï¸ß£¨£¾2 000 IU/mL£©µÄ»¼Õߣ¬Ó¦µ±³ÖÐøÖÎÁƵ½ºÍÃâÒß¹¦ÄÜÕý³£ÂýÐÔÒÒÐ͸ÎÑ×»¼ÕßͬÑùµÄÍ£Ò©±ê×¼£¨¢ó£©¡££¨3£©¶ÔÓÚÔ¤ÆÚÁƳ̡Ü12¸öÔµĻ¼Õߣ¬¿ÉÒÔÑ¡ÓÃÀÃ×·ò¶¨£¨¢ñ£©»òÌæ±È·ò¶¨£¨¢ó£©¡££¨4£©¶ÔÓÚÔ¤ÆÚÁƳ̸ü³¤µÄ»¼Õߣ¬Ó¦ÓÅÏÈÑ¡Óö÷Ìæ¿¨Î¤»ò°¢µÂ¸£Î¤õ¥£¨¢ó£©¡££¨5£©ºËÜÕ (Ëá) ÀàËÆÎïÍ£Óúó¿É³öÏÖ¸´·¢£¬ÉõÖÁ²¡Çé¶ñ»¯£¬Ó¦ÓèÒԸ߶ÈÖØÊÓ¡££¨6£©¸ÉÈÅËØÓйÇËèÒÖÖÆ×÷Óã¬Ó¦µ±±ÜÃâÑ¡Óᣠ¡¡¡¡£¨ËÄ£©HBV/HCV ºÏ²¢¸ÐȾ»¼ÕßµÄÖÎÁÆ ¡¡¡¡¶Ô´ËÀ໼ÕßÓ¦ÏÈÈ·¶¨ÊÇÄÇÖÖ²¡¶¾Õ¼ÓÅÊÆ£¬È»ºó¾ö¶¨ÈçºÎÖÎÁÆ¡£È综ÕßHBV DNA¡Ý104¿½±´/mL£¬¶øHCV RNA²â²»µ½£¬ÔòÓ¦ÏÈÖÎÁÆHBV¸ÐȾ¡£¶ÔHBV DNAˮƽ¸ßÇҿɼì²âµ½HCV RNAÕߣ¬Ó¦ÏÈÓñê×¼¼ÁÁ¿¾ÛÒÒ¶þ´¼»¯¸ÉÈÅËØºÍÀû°ÍΤÁÖÖÎÁÆ3¸öÔ£¬ÈçHBV DNAÎÞÓ¦´ð»òÉý¸ß£¬Ôò¼ÓÓÃÀÃ×·ò¶¨»ò¶÷Ìæ¿¨Î¤»ò°¢µÂ¸£Î¤õ¥ÖÎÁÆ¡£ ¡¡¡¡£¨Î壩HBVºÍHIVºÏ²¢¸ÐȾ»¼ÕßµÄÖÎÁÆ ¡¡¡¡¶ÔÓÚ·ûºÏÂýÐÔÒÒÐ͸ÎÑ׿¹²¡¶¾ÖÎÁƱê×¼µÄ»¼ÕßÓ¦µ±ÊµÊ©ÖÎÁÆ£¨¢ó£©¡£¶ÔÒ»¹ýÐÔ»òÇá΢ALTÉý¸ß£¨1~2¡ÁULN£©µÄ»¼Õߣ¬Ó¦µ±¿¼ÂǸλî¼ì£¨¢ò-3£©¡£ ¡¡¡¡¶ÔÓÚδ½øÐÐHAARTÖÎÁƺͽüÆÚ²»ÐèÒª½øÐÐHAARTÖÎÁƵϼÕߣ¨CD 4£¾500£¯mm3£©£¬Ó¦Ñ¡ÓÃÎÞ¿¹HIV»îÐÔµÄÒ©Îï½øÐп¹ÒÒÐ͸ÎÑײ¡¶¾ÖÎÁÆ£¬ÀýÈç¾ÛÒÒ¶þ´¼»¯¸ÉÈÅËØ¦Á»ò°¢µÂ¸£Î¤õ¥¡£ ¡¡¡¡¶ÔÓÚÕýÔÚ½ÓÊÜÓÐЧHARRTÖÎÁƵϼÕߣ¬ÈôHARRT·½°¸ÖÐÎÞ¿¹ÒÒÐ͸ÎÑײ¡¶¾Ò©ÎÔò¿ÉÑ¡ÓþÛÒÒ¶þ´¼»¯¸ÉÈÅËØ¦Á»ò°¢µÂ¸£Î¤õ¥ÖÎÁÆ£¨¢ò-3£©¡£¶ÔÓÚÀÃ×·ò¶¨ÄÍÒ©»¼Õߣ¬Ó¦µ±¼ÓÓð¢µÂ¸£Î¤õ¥ÖÎÁÆ£¨¢ó£©¡£ ¡¡¡¡µ±ÐèÒª¸Ä±äHAART·½°¸Ê±£¬³ý·Ç»¼ÕßÒѾ»ñµÃHBeAgѪÇåת»»¡¢²¢Íê³ÉÁË×ã¹»µÄ¹®¹ÌÖÎÁÆÊ±¼ä£¬²»Ó¦µ±ÔÚÎÞÓÐЧҩÎïÌæ´úǰ¾ÍÖжϿ¹ÒÒÐ͸ÎÑײ¡¶¾µÄÓÐЧҩÎ¢ò-3£©¡£ ¡¡¡¡£¨Áù£©ÒÒÐ͸ÎÑ×µ¼ÖµĸÎË¥½ß ¡¡¡¡ÓÉÓڴ󲿷ּ±ÐÔÒÒÐ͸ÎÑ׳Ê×ÔÏÞÐÔ¾¹ý£¬Òò´Ë²»ÐèÒª³£¹æ¿¹²¡¶¾ÖÎÁÆ¡£µ«¶Ô²¿·ÖÖØ¶È»òǨÑÓ¡¢ÓÐÖØÖ¢ÇãÏòÕߣ¬Ó¦¸Ã¸øÓ迹²¡¶¾ÖÎÁÆ£¨III£©¡£ ¡¡¡¡HBV¸ÐȾËùÖµĸÎË¥½ß£¬°üÀ¨¼±ÐÔ¡¢ÑǼ±ÐÔ¡¢Âý¼Ó¼±ÐÔºÍÂýÐÔ¸ÎË¥½ß£¬Ö»ÒªHBVDNA¿É¼ì³ö£¬¾ùӦʹÓúËÜÕ£¨ËᣩÀàËÆÎ²¡¶¾ÖÎÁÆ[106]£¨III£©¡£ ¡¡¡¡£¨Æß£©ÒÒÐ͸ÎÑ×µ¼ÖµÄÔ·¢ÐÔ¸Îϸ°û°©£¨HCC£© ¡¡¡¡³õ²½Ñо¿ÏÔʾ£¬HCC¸ÎÇгýÊõʱHBV DNAˮƽÊÇÔ¤²âÊõºó¸´·¢µÄ¶ÀÁ¢Î£ÏÕÒòËØÖ®Ò»[107]£¬ÇÒ¿¹²¡¶¾ÖÎÁÆ¿ÉÏÔÖøÑÓ³¤¸Î°©»¼ÕßµÄÉú´æÆÚ[108]£¬Òò´Ë£¬¶ÔHBV DNAÑôÐԵķÇÖÕÄ©ÆÚHCC»¼Õß½¨ÒéÓ¦ÓúËÜÕ£¨ËᣩÀàËÆÎ²¡¶¾ÖÎÁÆ¡£ ¡¡¡¡£¨°Ë£©¸ÎÒÆÖ²»¼Õß ¡¡¡¡¶ÔÓÚÄâ½ÓÊܸÎÒÆÖ²ÊÖÊõµÄHBVÏà¹Ø¼²²¡»¼Õߣ¬ÈçHBV DNA¿É¼ì²âµ½£¬×îºÃÓÚ¸ÎÒÆÖ²Êõǰ1~3¸öÔ¿ªÊ¼·þÓÃÀÃ×·ò¶¨£¬Ã¿ÈÕ 100 mg¿Ú·þ£»ÊõÖÐÎÞ¸ÎÆÚ¸øÓèHBIG£»Êõºó³¤ÆÚʹÓÃÀÃ×·ò¶¨ºÍС¼ÁÁ¿HBIG (µÚ1ÖÜÿÈÕ800 IU£¬ÒÔºóÿÖÜ800 IUÖÁÿÔÂÓ¦ÓÃ800 U) (II)£¬²¢¸ù¾Ý¿¹-HBsˮƽµ÷ÕûHBIG¼ÁÁ¿ºÍÓÃÒ©¼ä¸ô (Ò»°ã¿¹-HBs¹ÈֵŨ¶ÈÓ¦´óÓÚ100~150 mIU/mL£¬Êõºó°ëÄêÄÚ×îºÃ´óÓÚ500 mIU/mL)£¬µ«ÀíÏëµÄÁƳÌÓдý½øÒ»²½È·¶¨ (II-1)¡£¶ÔÓÚ·¢ÉúÀÃ×·ò¶¨ÄÍÒ©Õߣ¬¿ÉÑ¡ÓÃÆäËûÒÑÅú×¼µÄÄÜÖÎÁÆÄÍÒ©±äÒìµÄºËÜÕ (Ëá) ÀàËÆÎï¡£ÁíÍ⣬¶ÔÓÚ¸´·¢µÍΣÕߣ¨¸ÎÒÆÖ²ÊõǰHBVDNAÒõÐÔ£¬ÒÆÖ²ºó2ÄêHBVδ¸´·¢£©£¬¿É¿¼ÂDzÉÓÃÀÃ×·ò¶¨¼Ó°¢µÂ¸£Î¤õ¥ÁªºÏÔ¤·À£¨II£© ¡¡¡¡£¨¾Å£©ÈÑÉïÏà¹ØÇé¿ö´¦Àí ¡¡¡¡ÓýÁäÆÚÅ®ÐÔÂýÐÔÒÒÐ͸ÎÑ×»¼Õߣ¬ÈôÓÐÖÎÁÆÊÊÓ¦Ö¢£¬Î´ÈÑÉïÕß¿ÉÓ¦ÓøÉÈÅËØ»òºËÜÕ£¨ËᣩÀàËÆÎïÖÎÁÆ£¬²¢ÇÒÔÚÖÎÁÆÆÚ¼äÓ¦²ÉÈ¡¿É¿¿´ëÊ©±ÜÔУ¨I£©¡£ ¡¡¡¡ÔÚ¿Ú·þ¿¹²¡¶¾Ò©ÎïÖÎÁƹý³ÌÖз¢ÉúÈÑÉïµÄ»¼Õߣ¬ÈôÓ¦ÓõÄÊÇÀÃ×·ò¶¨»òÆäËüÈÑÉïB¼¶Ò©Îï£¨Ìæ±È·ò¶¨»òÌæÅµ¸£Î¤£©£¬ÔÚ³ä·Ö¸æÖª·çÏÕ¡¢È¨ºâÀû±×¡¢»¼ÕßÇ©ÊðÖªÇéͬÒâÊéµÄÇé¿öÏ£¬ÖÎÁƿɼÌÐø¡£ ¡¡¡¡ÈÑÉïÖгöÏÖÒÒÐ͸ÎÑ×·¢×÷Õߣ¬ÊÓ²¡Çé³Ì¶È¾ö¶¨ÊÇ·ñ¸øÓ迹²¡¶¾ÖÎÁÆ£¬ÔÚ³ä·Ö¸æÖª·çÏÕ¡¢È¨ºâÀû±×£¬»¼ÕßÇ©ÊðÖªÇéͬÒâÊéµÄÇé¿öÏ£¬¿ÉÒÔʹÓÃÀÃ×·ò¶¨£¬Ìæ±È·ò¶¨»òÌæÅµ¸£Î¤ÖÎÁÆ£¨III£©¡£ ¡¡¡¡£¨Ê®£©¶ùͯ»¼Õß ¡¡¡¡¶ÔÓÚ12ËêÒÔÉÏ£¨ÌåÖØ¡Ý35kg£©ÂýÐÔÒÒÐ͸ÎÑ×»¼¶ù£¬ÆäÆÕͨIFN-a ÖÎÁƵÄÊÊÓ¦Ö¤¡¢ÁÆÐ§¼°°²È«ÐÔÓë³ÉÈËÏàËÆ[53]£¬¼ÁÁ¿Îª3~6 MU/m2£¬×î´ó¼ÁÁ¿²»³¬¹ý10 MU/m2 (¢ò)¡£ÔÚÖªÇéͬÒâµÄ»ù´¡ÉÏ£¬Ò²¿É°´³ÉÈ˵ļÁÁ¿ºÍÁƳÌÓÃÀÃ×·ò¶¨ÖÎÁÆ (I)£¬»ò°¢µÂ¸£Î¤õ¥[109]¡£ ¡¡¡¡Ê®Æß¡¢¿¹Ñס¢¿¹Ñõ»¯ºÍ±£¸ÎÖÎÁÆ ¡¡¡¡HBVËùÖµĸÎÔàÑ×Ö¢»µËÀ¼°ÆäËùÖµĸÎÏËά»¯ÊǼ²²¡½øÕ¹µÄÖ÷Òª²¡Àíѧ»ù´¡¡£¸Ê²ÝËáÖÆ¼Á¡¢Ë®·É¼»ËØÖƼÁ¡¢¶à²»±¥ºÍÂÑÁ×Ö¬ÖÆ¼ÁÒÔ¼°Ë«»·´¼µÈ£¬Óв»Í¬³Ì¶ÈµÄ¿¹Ñס¢¿¹Ñõ»¯¡¢±£»¤¸Îϸ°ûĤ¼°Ï¸°ûÆ÷µÈ×÷Óã¬ÁÙ´²Ó¦ÓÿɸÄÉÆ¸ÎÔàÉú»¯Ñ§Ö¸±ê (¢ò-2£¬II-3)¡£ ¡¡¡¡¿¹Ñ×±£¸ÎÖÎÁÆÖ»ÊÇ×ÛºÏÖÎÁƵÄÒ»²¿·Ö£¬²¢²»ÄÜÈ¡´ú¿¹²¡¶¾ÖÎÁÆ¡£¶ÔÓÚALTÃ÷ÏÔÉý¸ßÕß»ò¸Î×é֯ѧÃ÷ÏÔÑ×Ö¢»µËÀÕߣ¬ÔÚ¿¹²¡¶¾ÖÎÁƵĻù´¡ÉÏ¿ÉÊʵ±Ñ¡Óÿ¹Ñ×±£¸ÎÒ©Îï¡£²»ÒËͬʱӦ ÓöàÖÖ¿¹Ñ×±£¸ÎÒ©ÎÒÔÃâ¼ÓÖØ¸ÎÔฺµ£¼°ÒòÒ©Îï¼äÏ໥×÷ÓöøÒýÆð²»Á¼Ð§Ó¦¡£ ¡¡¡¡Ê®°Ë¡¢¿¹ÏËά»¯ÖÎÁÆ ¡¡¡¡ÓÐÑо¿±íÃ÷£¬¾IFN-a»òºËÜÕ (Ëá) ÀàËÆÎ²¡¶¾ÖÎÁƺ󣬴ӸÎ×éÖ¯²¡Àíѧ¿É¼ûÏËά»¯ÉõÖÁ¸ÎÓ²»¯ÓÐËù¼õÇá¡£Òò´Ë£¬¿¹²¡¶¾ÖÎÁÆÊÇ¿¹ÏËά»¯ÖÎÁƵĻù´¡¡£ ¡¡¡¡¶à¸ö¿¹¸ÎÏËά»¯ÖгÉÒ©·½¼ÁÔÚʵÑéºÍÁÙ´²Ñо¿ÖÐÏÔʾһ¶¨ÁÆÐ§£¬µ«ÐèÒª½øÒ»²½½øÐдóÑù±¾¡¢Ëæ»ú¡¢Ë«Ã¤ÁÙ´²ÊÔÑ飬²¢ÖØÊÓ¸Î×é֯ѧ¼ì²é½á¹û£¬ÒÔ½øÒ»²½ÑéÖ¤ÆäÁÆÐ§¡£ ¡¡¡¡Ê®¾Å¡¢»¼ÕßËæ·Ã ¡¡¡¡ ÖÎÁƽáÊøºó£¬²»ÂÛÓÐÎÞÖÎÁÆÓ¦´ð£¬Í£Ò©ºó°ëÄêÄÚÖÁÉÙÿ2¸öÔ¼ì²â1´ÎALT¡¢AST¡¢ÑªÇ嵨ºìËØ (±ØÒªÊ±)¡¢HBVѪÇåѧ±êÖ¾ºÍHBV DNA£¬ÒÔºóÿ3~6¸öÔ¼ì²â1´Î£¬ÖÁÉÙËæ·Ã12¸öÔ¡£Ëæ·ÃÖÐÈçÓв¡Çé±ä»¯£¬Ó¦Ëõ¶ÌËæ·Ã¼ä¸ô¡£ ¡¡¡¡¶ÔÓÚ³ÖÐøALTÕý³£ÇÒHBV DNAÒõÐÔÕߣ¬½¨ÒéÖÁÉÙÿ6¸öÔ½øÐÐHBV DNA¡¢ALT¡¢AFPºÍ³¬ÉùÏÔÏñ¼ì²é¡£¶ÔÓÚALTÕý³£µ«HBV DNAÑôÐÔÕߣ¬½¨Òéÿ3¸öÔ¼ì²â1´ÎHBV DNAºÍALT£¬Ã¿6¸öÔ½øÐÐAFPºÍ³¬ÉùÏÔÏñ¼ì²é£»±ØÒªÊ±Ó¦×÷¸Î×é֯ѧ¼ì²é¡£ ¡¡¡¡¶ÔÓÚÂýÐÔÒÒÐ͸ÎÑס¢¸ÎÓ²»¯»¼Õߣ¬ÌرðÊÇHCC¸ßΣ»¼Õß (£¾40Ë꣬ÄÐÐÔ¡¢ÊȾơ¢¸Î¹¦Äܲ»È«»òÒÑÓÐAFPÔö¸ßÕß)£¬Ó¦Ã¿3~6¸öÔ¼ì²âAFPºÍ¸¹²¿³¬ÉùÏÔÏñ (±ØÒªÊ±×÷CT»òMRI)£¬ÒÔÔçÆÚ·¢ÏÖHCC¡£¶Ô¸ÎÓ²»¯»¼Õß»¹Ó¦Ã¿1~2Äê½øÐÐθ¾µ¼ì²é»òÉÏÏû»¯µÀXÏßÔìÓ°£¬ÒÔ¹Û²ìÓÐÎÞʳ¹Üθµ×¾²ÂöÇúÕż°Æä½øÕ¹Çé¿ö¡£
¸½1.±¾Ö¸ÄÏÍÆ¼öÒâ¼ûËùÒÀ¾ÝµÄÖ¤¾Ý·Ö¼¶[110]
Ö¤¾ÝµÈ¼¶ |
¶¨ Òå |
¢ñ |
Ëæ»ú¶ÔÕÕÁÙ´²ÊÔÑé |
¢ò-1 |
ÓжÔÕÕµ«·ÇËæ»úÁÙ´²ÊÔÑé |
¢ò-2 |
¶ÓÁÐÑо¿»ò²¡Àý¶ÔÕÕÑо¿ |
¢ò-3 |
¶àʱ¼äµã²¡ÀýϵÁзÖÎö£¬½á¹ûÃ÷ÏԵķǶÔÕÕÊÔÑé |
¢ó |
ÊÜ×ðÖØÈ¨ÍþµÄ¹Ûµã¼°ÃèÊöÐÔÁ÷Ðв¡Ñ§Ñо¿ | ¸½2¡¢¿¹²¡¶¾ÖÎÁÆÓ¦´ðÏà¹ØÃû´Ê½âÊÍ[26, 29-31] ¡¡¡¡1. ²¡¶¾Ñ§Ó¦´ð (virological response) ָѪÇåHBV DNA¼ì²â²»µ½ (PCR·¨) »òµÍÓÚ¼ì²âÏÂÏÞ£¨ÍêÈ«²¡¶¾Ñ§Ó¦´ð£¬complete virologic response)£¬»ò½Ï»ùÏßϽµ¡Ý2 log IU/mL£¨²¿·Ö²¡¶¾Ñ§Ó¦´ð£¬partial virologic response)¡£ ¡¡¡¡2. ѪÇåѧӦ´ð (serological response) ָѪÇåHBeAgתÒõ»òHBeAgѪÇåѧת»»£¬»òHBsAgתÒõ»òHBsAgѪÇåѧת»»¡£ ¡¡¡¡3. Éú»¯Ñ§Ó¦´ð (biochemical response) ָѪÇåALTºÍAST»Ö¸´Õý³£¡£ ¡¡¡¡4. ×é֯ѧӦ´ð (histological response) Ö¸¸ÎÔà×é֯ѧÑ×Ö¢»µËÀ»òÏËά»¯³Ì¶È¸ÄÉÆ´ïµ½Ä³Ò»¹æ¶¨Öµ¡£ ¡¡¡¡5. Ô·¢ÐÔÖÎÁÆÊ§°Ü(primary treatment failure) ÔÚÒÀ´ÓÐÔÁ¼ºÃµÄÇé¿öÏ£¬ÓúËÜÕ£¨ËᣩÀàËÆÎïÖÎÁÆ3¸öÔÂʱϽµÐ¡ÓÚ1log IU/mL»ò6¸öÔÂʱHBV-DNAϽµÐ¡ÓÚ2 log IU/mL ¡¡¡¡6. ²¡¶¾Ñ§Í»ÆÆ (virological breakthrough) ÔÚδ¸ü¸ÄÖÎÁƵÄÇé¿öÏ£¬HBV DNAˮƽ±ÈÖÎÁÆÖÐ×îµÍµãÉÏÉý1logÖµ£¬»òÒ»¶ÈתÒõºóÓÖתΪÑôÐÔ£¬¿ÉÓлòÎÞALTÉý¸ß¡£ ¡¡¡¡7. Éú»¯Ñ§Í»ÆÆ (biochemical breakthrough) ³£·¢ÉúÔÚ²¡¶¾Ñ§Í»ÆÆºó£¬±íÏÖΪALT»ò/ºÍAST¸´³£ºó£¬ÔÚδ¸ü¸ÄÖÎÁƵÄÇé¿öÏÂÔÙ¶ÈÉý¸ß£¬µ«Ó¦ÅųýÓÉÆäËûÒòËØÒýÆðµÄALTºÍASTÉý¸ß¡£ ¡¡¡¡8. ά³ÖÓ¦´ð (maintained response) ÔÚ¿¹²¡¶¾ÖÎÁÆÆÚ¼äHBV DNA¼ì²â²»µ½ (PCR·¨) »òµÍÓÚ¼ì²âÏÂÏÞ£¬»òALTÕý³£¡£ ¡¡¡¡9. ÖÎÁƽáÊøÊ±Ó¦´ð (end-of-treatment response) ÖÎÁƽáÊøÊ±µÄ²¡¶¾Ñ§¡¢ÑªÇåѧ¡¢Éú»¯Ñ§»ò×é֯ѧӦ´ð¡£ ¡¡¡¡10. ³ÖÐøÓ¦´ð (sustained response) ÖÎÁƽáÊøºóËæ·Ã6¸öÔ»ò12¸öÔÂÒÔÉÏ£¬ÁÆÐ§Î¬³Ö²»±ä£¬ÎÞ¸´·¢¡£ ¡¡¡¡11. ¸´·¢ (relapse) ÖÎÁƽáÊøÊ±³öÏÖ²¡¶¾Ñ§Ó¦´ð£¬µ«Í£Ò©ºóHBV DNAÖØÐÂÉý¸ß»òÑôת£¬°éÓÐALTºÍASTÉý¸ß£¬µ«Ó¦ÅųýÓÉÆäËûÒòËØÒýÆðµÄALTºÍASTÉý¸ß¡£ ¡¡¡¡12. ÄÍÒ©£¨Drug resistance£©ÔÚ¿¹²¡¶¾ÖÎÁƹý³ÌÖУ¬¼ì²âµ½ºÍHBVÄÍÒ©Ïà¹ØµÄ»ùÒòÍ»±ä£¬ ³ÆÎª»ùÒòÐÍÄÍÒ©£¨Genotypic resistance£©¡£ÌåÍâʵÑéÏÔʾ¿¹²¡¶¾Ò©ÎïÃô¸ÐÐÔ½µµÍ¡¢²¢ºÍ»ùÒòÄÍÒ©Ïà¹Ø£¬³ÆÎª±íÐÍÄÍÒ©£¨Phenotypic resistance£©¡£Õë¶ÔÒ»ÖÖ¿¹²¡¶¾Ò©Îï³öÏÖµÄÄÍÒ©Í»±ä¶ÔÁíÍâÒ»ÖÖ»ò¼¸ÖÖ¿¹²¡¶¾Ò©ÎïÒ²³öÏÖÄÍÒ©£¬³ÆÎª½»²æÄÍÒ©£¨Cross resistance£©¡£
¸½3. ÂýÐÔÒÒÐ͸ÎÑ×ÖÎÁÆÒ»°ãÁ÷³Ìͼ
¡¡¡¡
¡¡¡¡²Î¿¼ÎÄÏ×
[1] ÖлªÒ½Ñ§»á¸Î²¡Ñ§·Ö»á¡¢¸ÐȾ²¡Ñ§·Ö»á. ÂýÐÔÒÒÐ͸ÎÑ×·ÀÖÎÖ¸ÄÏ. Öлª¸ÎÔಡÔÓÖ¾, 2005,13(12):881-891. ¡¡¡¡[2] Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev, 2000,64(1):51-68. ¡¡¡¡[3] Scaglioni PP, Melegari M, Wands JR. Biologic properties of hepatitis B viral genomes with mutations in the precore promoter and precore open reading frame. Virology, 1997,233(2):374-81. ¡¡¡¡[4] Tran TT, Trinh TN, Abe K. New complex recombinant genotype of hepatitis B virus identified in Vietnam. J Virol, 2008,82(11):5657-63. ¡¡¡¡[5] Olinger CM, Jutavijittum P, Hubschen JM, et al. Possible new hepatitis B virus genotype, southeast Asia. Emerg Infect Dis, 2008,14(11):1777-80. ¡¡¡¡[6] Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology, 2002,122(7):1756-62. ¡¡¡¡[7] Chu CM, Liaw YF. Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. J Hepatol, 2005,43(3):411-7. ¡¡¡¡[8] Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst, 2005,97(4):265-72. ¡¡¡¡[9] Zhang HW, Yin JH, Li YT, et al. Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China. Gut, 2008,57(12):1713-20. ¡¡¡¡[10] Hou J, Schilling R, Janssen HL, et al. Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance. J Med Virol, 2007,79(8):1055-63. ¡¡¡¡[11] Jardi R, Rodriguez-Frias F, Schaper M, et al. Analysis of hepatitis B genotype changes in chronic hepatitis B infection: Influence of antiviral therapy. J Hepatol, 2008,49(5):695-701. ¡¡¡¡[12] Liu CJ, Kao JH. Genetic variability of hepatitis B virus and response to antiviral therapy. Antivir Ther, 2008,13(5):613-24. ¡¡¡¡[13] Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med, 2004,350(11):1118-29. ¡¡¡¡[14] Organization., W. H. Hepatitis B. World Health Organization Fact Sheet 204 dex. (Revised October 2000). WHO Web site .http://www.who.int/mediacentre/ factsheets/fs204/en/ in html . ¡¡¡¡[15] Liang X, Bi S, Yang W, et al. Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination. Vaccine, 2009,27(47):6550-7. ¡¡¡¡[16] Liang X, Bi S, Yang W, et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China. J Infect Dis, 2009,200(1):39-47. ¡¡¡¡[17] Lu FM, Zhuang H. Management of hepatitis B in China. Chin Med J (Engl), 2009,122(1):3-4. ¡¡¡¡[18] Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep, 2005,54(RR-16):1-31. ¡¡¡¡[19] Hepatitis B.http://www.who.int/csr/disease/hepatitis/ whocdscsrlyo2002 2./ou/ . ¡¡¡¡[20] Lai CL, Ratziu V, Yuen MF, et al. Viral hepatitis B. Lancet, 2003,362(9401):2089-94. ¡¡¡¡[21] Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int, 2009,29 Suppl 1:100-7. ¡¡¡¡[22] Hui CK, Leung N, Yuen ST, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology, 2007,46(2):395-401. ¡¡¡¡[23] McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology, 2009,49(5 Suppl):S45-55. ¡¡¡¡[24] Liaw YF. Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy. J Gastroenterol Hepatol, 2003,18(3):246-52. ¡¡¡¡[25] Chu CM, Hung SJ, Lin J, et al. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med, 2004,116(12):829-34. ¡¡¡¡[26] Fattovich G, Brollo L, Alberti A, et al. Long-term follow-up of anti-HBe-positive chronic active hepatitis B. Hepatology, 1988,8(6):1651-4. ¡¡¡¡[27] Brunetto MR, Oliveri F, Rocca G, et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology, 1989,10(2):198-202. ¡¡¡¡[28] Di MV, Lo IO, Camma C, et al. The long-term course of chronic hepatitis B. Hepatology, 1999,30(1):257-64. ¡¡¡¡[29] Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis, 2006,26(2):142-52. ¡¡¡¡[30] Chen YC, Chu CM, Yeh CT, et al. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. Hepatol Int, 2007,1(1):267-73. ¡¡¡¡[31] Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology, 2002,35(6):1522-7. ¡¡¡¡[32] Chou YC, Yu MW, Wu CF, et al. Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma. Gut, 2008,57(1):91-7. ¡¡¡¡[33] Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA, 2006,295(1):65-73. ¡¡¡¡[34] Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med, 2002,347(3):168-74. ¡¡¡¡[35] Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology, 2006,130(3):678-86. ¡¡¡¡[36] Tai DI, Chen CH, Chang TT, et al. Eight-year nationwide survival analysis in relatives of patients with hepatocellular carcinoma: role of viral infection. J Gastroenterol Hepatol, 2002,17(6):682-9. ¡¡¡¡[37] Öйú¼²²¡Ô¤·À¿ØÖÆÖÐÐÄ. ÒÒÐ͸ÎÑ×ÒßÃç¶ùͯ¼Æ»®ÃâÒß¼¼Êõ¹ÜÀí¹æ³Ì (ÊÔÐÐ). 2002. ¡¡¡¡[38] ÏĹúÁ¼, ¹¨½¡, Íõ¼Ì½Ü, µÈ. ÖØ×éÒÒÐ͸ÎÑ×ÒßÃç×è¶ÏÒÒÐ͸ÎÑײ¡¶¾Ä¸Ó¤´«²¥·½°¸µÄ±£»¤Ð§¹ûÆÀ¼Û. ÖлªÁ÷Ðв¡Ñ§ÔÓÖ¾, 2003,24(5):362-365. ¡¡¡¡[39] ÐÏÓñÀ¼; ¹¨Ïþºì; ÖÜÉÜÁ«,µÈ. ×è¶ÏΧ²úÆÚĸӤ´«²¥×î¼ÑÃâÒß·½°¸µÄÑо¿[J]. ÖлªÊµÑéºÍÁÙ´²²¡¶¾Ñ§ÔÓÖ¾, 1990, 4:-488 . ¡¡¡¡[40] CDC. Hepatitis B. http://www.cdc.gov/ncidod/diseases/hepatitis/b/ education/hbv_and_you_chi.pdf WHO . ¡¡¡¡[41] Hepatitis B and breastfeeding. http://www.who.int /child-adolescent-health/New_Publications /NUTRITION/updt-22.htm (online on Oct 23, 2005)[J] . ¡¡¡¡[42] Zanetti AR, Mariano A, Romano L, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet, 2005,366(9494):1379-84. ¡¡¡¡[43] John TJ, Cooksley G. Hepatitis B vaccine boosters: is there a clinical need in high endemicity populations. J Gastroenterol Hepatol, 2005,20(1):5-10. ¡¡¡¡[44] Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis. MMWR Recomm Rep, 2001,50(RR-11):1-52. ¡¡¡¡[45] ²¡¶¾ÐÔ¸ÎÑ×·ÀÖη½°¸. ²¡¶¾ÐÔ¸ÎÑ×·ÀÖη½°¸. Öлª¸ÎÔಡÔÓÖ¾, 2000,8(6):324. ¡¡¡¡[46] Pawlotsky JM, Dusheiko G, Hatzakis A, et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology, 2008,134(2):405-15. ¡¡¡¡[47] Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol, 2007,102(11):2589-600. ¡¡¡¡[48] Scott DR, Levy MT. Liver transient elastography (Fibroscan): a place in the management algorithms of chronic viral hepatitis. Antivir Ther, 2010,15(1):1-11. ¡¡¡¡[49] Lin SM, Yu ML, Lee CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol, 2007,46(1):45-52. ¡¡¡¡[50] Piratvisuth T, Lau G, Chao YC, et al. Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatol Int, 2008,2(1):102-10. ¡¡¡¡[51] Chan HL, Leung NW, Hui AY, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med, 2005,142(4):240-50. ¡¡¡¡[52] Flink HJ, van ZM, Hansen BE, et al. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol, 2006,101(2):297-303. ¡¡¡¡[53] Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology, 2008,135(2):459-67. ¡¡¡¡[54] Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology, 2009,136(7):2169-2179.e1-4. ¡¡¡¡[55] Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology, 2007,45(2):507-39. ¡¡¡¡[56] Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol, 2006,4(8):936-62. ¡¡¡¡[57] Fried MW, Piratvisuth T, Lau GK, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology, 2008,47(2):428-34. ¡¡¡¡[58] Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology, 2009,49(4):1151-7. ¡¡¡¡[59] Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology, 2009,49(4):1141-50. ¡¡¡¡[60] Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology, 2003,125(6):1714-22. ¡¡¡¡[61] Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med, 1998,339(2):61-8. ¡¡¡¡[62] Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology, 2000,119(1):172-80. ¡¡¡¡[63] Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med, 1999,341(17):1256-63. ¡¡¡¡[64] Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology, 1999,30(3):770-4. ¡¡¡¡[65] Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology, 2003,124(1):105-17. ¡¡¡¡[66] Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med, 2004,351(15):1521-31. ¡¡¡¡[67] Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology, 2000,31(1):207-10. ¡¡¡¡[68] Perrillo RP, Wright T, Rakela J, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology, 2001,33(2):424-32. ¡¡¡¡[69] Hann HW, Fontana RJ, Wright T, et al. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl, 2003,9(1):49-56. ¡¡¡¡[70] Jonas MM, Mizerski J, Badia IB, et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med, 2002,346(22):1706-13. ¡¡¡¡[71] Figlerowicz M, Kowala-Piaskowska A, Filipowicz M, et al. Efficacy of lamivudine in the treatment of children with chronic hepatitis B. Hepatol Res, 2005,31(4):217-22. ¡¡¡¡[72] Ò¦¹âåö, ´ÞÕñÓî, Ò¦¼¯Â³, µÈ. ¹ú²úÀÃ×·ò¶¨ÖÎÁÆ2200ÀýÂýÐÔÒÒÐ͸ÎÑ׵ĢôÆÚÁÙ´²ÊÔÑé. Öлª¸ÎÔಡÔÓÖ¾, 2003,11(2):103-108. ¡¡¡¡[73] Ò¦¹âåö, Íõ±¦¶÷, ´ÞÕñÓî, µÈ. ÀÃ×·ò¶¨ÖÎÁÆÂýÐÔÒÒÐ͸ÎÑ×ÈýÄêÁÆÐ§¹Û²ì. ÖлªÄÚ¿ÆÔÓÖ¾, 2003,42(6):382-387. ¡¡¡¡[74] ÔøÃñµÂ, Ã©ÒæÃñ, Ò¦¹âåö, µÈ. °¢µÂ¸£Î¤õ¥ÖÎÁÆHBeAgÑôÐÔµÄÖйúÂýÐÔÒÒÐͲ¡¶¾ÐÔ¸ÎÑ×»¼Õß52ÖܵĶàÖÐÐÄÁÙ´²Ñо¿. Öлª´«È¾²¡ÔÓÖ¾, 2005,23(6):387-394. ¡¡¡¡[75] Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med, 2003,348(9):808-16. ¡¡¡¡[76] Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology, 2008,48(3):750-8. ¡¡¡¡[77] Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology, 2006,131(6):1743-51. ¡¡¡¡[78] Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med, 2005,352(26):2673-81. ¡¡¡¡[79] Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med, 2003,348(9):800-7. ¡¡¡¡[80] Lampertico P, Vigano M, Manenti E, et al. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology, 2007,133(5):1445-51. ¡¡¡¡[81] Rapti I, Dimou E, Mitsoula P, et al. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology, 2007,45(2):307-13. ¡¡¡¡¡¡¡¡[82] Lampertico P, Vigano M, Manenti E, et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology, 2005,42(6):1414-9. ¡¡¡¡[83] Peters MG, Hann HH, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology, 2004,126(1):91-101. ¡¡¡¡[84] Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology, 2004,126(1):81-90. ¡¡¡¡[85] Marzano A, Lampertico P, Mazzaferro V, et al. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transpl, 2005,11(5):532-8. ¡¡¡¡[86] ÕÅÑÅÃô, ÖìÖ¾¾ü, Ö£ºç, µÈ. °¢µÂ¸£Î¤ÔÚÔ¤·À¸ÎÒÆÖ²ºóÒҸθ´·¢ÖеÄ×÷ÓÃ. Öлª¸Îµ¨Íâ¿ÆÔÓÖ¾, 2006,12(5):313-315. ¡¡¡¡[87] Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med, 2006,354(10):1001-10. ¡¡¡¡[88] Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med, 2006,354(10):1011-20. ¡¡¡¡[89] Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology, 2007,133(5):1437-44. ¡¡¡¡[90] Yokosuka O, Takaguchi K, Fujioka S, et al. Long-term use of entecavir in nucleoside-naive Japanese patients with chronic hepatitis B infection. J Hepatol, 2010,52(6):791-9. ¡¡¡¡[91] Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology, 2006,130(7):2039-49. ¡¡¡¡[92] Ò¦¹âåö, ¼ÆìÍìÍ, Èκì, µÈ. ¶÷Ìæ¿¨Î¤ÖÎÁÆÀÃ×·ò¶¨Ê§Ð§ÂýÐÔÒÒÐ͸ÎÑ×Ò»ÄêµÄÁÆÐ§. Öлª´«È¾²¡ÔÓÖ¾, 2006,24(6):385-389. ¡¡¡¡[93] Ò¦¹âåö, Öìõ, ÍõÓîÃ÷, µÈ. ¶÷Ìæ¿¨Î¤ÓëÀÃ×·ò¶¨ÖÎÁÆÂýÐÔÒÒÐ͸ÎÑ×Ëæ»ú¡¢Ë«Ã¤¡¢Ë«Ä£Äâ¶ÔÕÕÑо¿. ÖлªÄÚ¿ÆÔÓÖ¾, 2006,45(11):891-895. ¡¡¡¡[94] Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology, 2009,136(2):486-95. ¡¡¡¡[95] Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med, 2007,357(25):2576-88. ¡¡¡¡[96] Hou J, Yin YK, Xu D, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Hepatology, 2008,47(2):447-54. ¡¡¡¡[97] Zeuzem S, Gane E, Liaw YF, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol, 2009,51(1):11-20. ¡¡¡¡[98] ¼Ö¼Ì¶«, ºî½ðÁÖ, ÒüÓпí, µÈ. Ìæ±È·ò¶¨»òÀÃ×·ò¶¨¿¹ÒÒÐ͸ÎÑײ¡¶¾µÄÁÆÐ§Ô¤²â̽ÌÖ. Öлª¸ÎÔಡÔÓÖ¾, 2007,15(5):342-345. ¡¡¡¡[99] Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med, 2008,359(23):2442-55. ¡¡¡¡[100] Heathcote EJ, Marcellin P, Buti M, et al. Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B. Gastroenterology, 2010. ¡¡¡¡[101] Yuen MF, Fong DY, Wong DK, et al. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology, 2007,46(6):1695-703. ¡¡¡¡[102] Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol, 2007,5(8):890-7. ¡¡¡¡[103] Chan HL, Tang JL, Tam W, et al. The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis. Aliment Pharmacol Ther, 2001,15(12):1899-905. ¡¡¡¡[104] Chien RN, Liaw YF, Chen TC, et al. Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology, 1998,27(5):1383-7. ¡¡¡¡[105] Hui CK, Cheung WW, Zhang HY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology, 2006,131(1):59-68. ¡¡¡¡[106] ÖлªÒ½Ñ§»á¸ÐȾ²¡Ñ§·Ö»á¸ÎË¥½ßÓëÈ˹¤¸Îѧ×é, ÖлªÒ½Ñ§»á¸Î²¡Ñ§·Ö»áÖØÐ͸β¡ÓëÈ˹¤¸Îѧ×é, µÈ. ¸ÎË¥½ßÕïÁÆÖ¸ÄÏ. Öлª¸ÎÔಡÔÓÖ¾, 2006,14(9):643-646. ¡¡¡¡[107] Hung IF, Poon RT, Lai CL, et al. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am J Gastroenterol, 2008,103(7):1663-73. ¡¡¡¡[108] Koda M, Nagahara T, Matono T, et al. Nucleotide analogs for patients with HBV-related hepatocellular carcinoma increase the survival rate through improved liver function. Intern Med, 2009,48(1):11-7. ¡¡¡¡[109] Sokal EM, Kelly D, Wirth S, et al. The pharmacokinetics and safety of adefovir dipivoxil in children and adolescents with chronic hepatitis B virus infection. J Clin Pharmacol, 2008,48(4):512-7. ¡¡¡¡[110] Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology, 2004,39(3):857-61. ¡¡¡¡ |